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HIV must traverse the mucosal barriers in order to establish a clinical infection during 
sexual transmission in the female reproductive tract. The cervical tract of a pregnant 
woman produces a mucin-rich solid material called the cervical mucus plug, which 
prevents the entry of bacteria and other foreign substances from the vaginal tract 
into the uterus. Our laboratory found that the cervical mucins—but not the crude 
cervical mucus plugs—isolated and purified from the mucus plugs inhibit HIV-1 
infection in an in vitro cell-free inhibition assay. We aimed to characterize and 
compare the inhibition of cell-free and cell-associated HIV-1 strains by the crude 
cervical mucus plugs and purified cervical mucins. 
Fifty-two cervical mucus plugs were collected from women in labour in 6 M guanidine 
hydrochloride with protease inhibitors. The cervical mucus plugs were solubilised in 
6 M guanidine hydrochloride with protease inhibitors, centrifuged, dialysed against 
distilled water and lyophilized. The mucins were purified by caesium chloride density 
gradient ultracentrifugation and size exclusion chromatography, dialysed against 
distilled water and lyophilized. The lyophilized samples were reconstituted in cell 
culture medium and used in cell viability assays, after which they were probed 
against a panel of replication-competent strains of HIV-1 using functional assays. 
The crude cervical mucus plugs inhibited cell-free HIV-1 strains more potently than 
the purified mucins. Depending on the infecting HIV-1 strain, this potency varied 
between and within samples from different donors. The data from a FACS-based 
virus fusion assay showed that some crude cervical mucus plugs inhibit fusion 
between the virus and target cell. Interestingly, cell-to-cell transmission of HIV-1 
partially overcame the anti-viral activity of the crude cervical mucus plugs. 
Furthermore, despite the donor’s HIV status, the biochemical analysis of the purified 
cervical mucins showed comparable characteristics in terms of buoyancy in caesium 
chloride and guanidine hydrochloride, glycoprotein and protein contents, which were 
recapitulated in the HIV inhibition assays. 
In conclusion, the crude cervical mucus plugs can potently inhibit different strains of 
HIV-1 compared to the purified cervical mucins, and this potency is more 
pronounced in the HIV positive cohort compared to the HIV negative cohort.  
Declaration 
I, Baxolele Mhlekude, hereby declare that the work on which this thesis is based is 
my original work (except where acknowledgements indicate otherwise) and that 
neither the whole work nor any part of it has been, is being, or is to be submitted for 
another degree in the University of Cape Town or any other university. 
I empower the University of Cape Town to reproduce for the purpose of research 
either the whole or any portion of the contents in any manner whatsoever. 
Signature: 
Date: 14 November 2018 




“It takes a village to raise a child” as an African proverb goes. This strongly 
resonates with me, for I did not walk this journey alone, but kindly assisted in 
different ways by several people and stakeholders to whom I owe this achievement. 
I would like to thank my supervisor, Professor Anwar Suleman Mall, whom I have 
known since 2012 as a BSc Honours student in Medical Biochemistry at UCT and 
worked under his supervision until my PhD. Thank you Professor Mall for bringing 
out the best in me and you truly are the best. Maz’enethole kuwe Njinga-lwazi. 
I would like to extend my heartfelt gratitude to my co-supervisor in the TWINCORE, 
Germany, Professor Christine Goffinet, whom I have known since late 2014 as a 
DAAD exchange MSc student in her laboratory. In 2017/2018, I went back to her 
laboratory to complete my PhD under her supervision. Vielen Dank, Christine, für 
deine stetige Unterstützung. Ich freue mich bereits auf weitere Zusammenarbeit in 
deiner Gruppe. 
 
Allow me to thank the heads and directors of the departments and institutes in which 
I have worked during the pursuit of this PhD. I will start with Professor Delawir Kahn, 
the then head of the Department of Surgery at UCT and his successor, Professor 
Elmi Muller, for their kind support. I would also like to thank Professor Thomas 
Pietschmann, the director of the Institute of Experimental Virology in the 
TWINCORE, Germany, for welcoming me in his institute during my research visits. 
With lots of love, I dedicate this thesis to my family: Mlandeli Mhlekude, Nofirst 
Mhlekude, Zandile Mhlekude, Luyanda Mhlekude and Andiswa Mhlekude. Thanks a 
million to my aunt, Nolulamile Sigantsu, enkosi kakhulu maMzangwa ngento 
yonk’ondenzele yona, and also thanks to all the members of the extended family, I 
will forever be grateful for your selfless support. 
I would like to thank all the laboratory members with whom I have worked in the 
Mall’s Lab: Dr. Vuyolwethu Siyo, Dr. Santhoshan Pillay, Zoe Lotz, Marilyn Tyler, 
Lizzette Fick, Noluyolo Ngamani, Kathleen Kehoe, Isla McQuaid and Ellis Tsetse. I 
would also like to extend my gratitude to Dr. Mankgopo Kgatle for her kind 
assistance during this doctoral journey.  
                                                                                                                
 
  
To my colleagues in the AG Goffinet, thanks for being my siblings miles away from 
home during my research trips in Germany: Dr. Aurélie Ducroux, Dr. Shuting Xu, Dr. 
Carina Elsner, Sergej Franz, Fabian Pott, Vânia Passos, Aparna Ponnurangam, 
Julia Kazmierski, Angelina Malassa, Nils Kriedemann, and Ellen Ewald. Million 
thanks to all the members of the Institute of Experimental Virology in the 
TWINCORE, Ich sehr glücklich mit euch gearbeitet zu haben.   
Back home in the Eastern Cape, I would like to thank Professor Mana Lungisa 
Mdaka, Dr. Mphumzi Mdledle, Dr. Charles Businge, Mr. Phikolomzi Sidoyi, Mr. Jim 
Joseph, Miss. Bomkazi Gqaza and the fellow clinicians for kindly assisting me during 
the sample collection in Mthatha General Hospital. I would also like to extend my 
deeply felt gratitude to the members of our study cohort for kindly donating with their 
cervical mucus plugs. Ngokuzithoba, ndidlulisa umbulelo ongazenzisiyo kuni nonke 
zimbokodo zakowethu. 
To Dr. Dee Blackhurst of the Division of Chemical Pathology at the University of 
Cape Town, thank you very much for all your selfless support during my doctoral 
journey at UCT. 
Also many thanks to Dr. Henry Hairwadzi for all the great advices and wisdom that 
he kindly shared with me during the conduct of this PhD.     
Last but not least, I would like to thank my funders for the financial support: National 
Research Foundation-Deutscher Akademischer Austausch Dienst (NRF-DAAD), 
Poliomyelitis Research Foundation (PRF) and the Postgraduate Funding Office 
(PGFO) of the University of Cape Town.    
                                                                                                                
 
 
Table of Contents 
Abbreviations .........................................................................................................................1 
Symbols ...................................................................................................................................5 
Chapter – 1: Literature Review ..........................................................................................6 
1.1. Background...................................................................................................................6 
1.2. General overview of the mucus and mucosal tracts  ..............................................9 
1.2.1. Oculo-rhino-otolaryngeal tract.......................................................................... 10 
1.2.2. Respiratory tract ................................................................................................. 11 
1.2.3. Gastrointestinal tract.......................................................................................... 12 
1.2.4. Genitourinary tract ............................................................................................. 13 
1.3. Cervical mucus and the mucus plug...................................................................... 14 
1.4. Mucins ........................................................................................................................ 16 
1.4.1. Secreted gel-forming mucins ........................................................................... 18 
1.4.2. Secreted non-gel-forming mucins ................................................................... 19 
1.4.3. Membrane-bound mucins ................................................................................. 19 
1.4.4. Structural models of gel-forming mucins........................................................ 20 
1.5. Aspects of the cervical mucus/plug ....................................................................... 21 
1.5.1. Biochemical aspects of the cervical mucus/plug .......................................... 22 
1.5.2. Immunological aspects of the cervical mucus/plug ...................................... 23 
1.5.3. Clinical aspects of the cervical mucus/plug ................................................... 24 
1.6. The antimicrobial activities of the cervical mucins............................................... 25 
Chapter – 2: Aims and Objectives ................................................................................. 28 
2.1. Aims ............................................................................................................................ 28 
2.2. Objectives .................................................................................................................. 28 
Chapter – 3: Materials and Methods ............................................................................. 29 
3.1. Materials ..................................................................................................................... 29 
3.2. Ethics statement........................................................................................................ 29 
                                                                                                                
 
 
3.3. Study population and sample collection................................................................ 30 
3.4. Preparation of the crude cervical mucus plugs .................................................... 30 
3.5. Preparation of the purified cervical mucins........................................................... 30 
3.6. Sodium dodecyl sulphate polyacrylamide-gel electrophoresis.......................... 31 
3.7. Western blot analysis of the crude cervical mucus plug and purified mucins. 32 
3.8. CellTiter-Glo luminescent viability assays ............................................................ 32 
3.9. Production of the virus stocks and titration ........................................................... 33 
3.10. TZMbl cell-based luciferase assays .................................................................... 33 
3.11. Heat inactivation assays........................................................................................ 34 
3.12. Time-of-addition assays ........................................................................................ 34 
3.13. The -lactamase-based HIV-1 fusion assay ...................................................... 35 
3.14. Cell-to-cell infection assays .................................................................................. 35 
3.15. Jurkat T-cell-based infection assays in the context of cell-free virus ............. 36 
3.16. Statistical analysis .................................................................................................. 36 
Chapter – 4: Results .......................................................................................................... 37 
4.1. Clinical profile of the study cohort .......................................................................... 37 
4.2. Biochemical purification of the cervical mucins ................................................... 37 
4.3. Sodium dodecyl polyacrylamide-gel electrophoresis .......................................... 39 
4.4. Western blot identification of the gel-forming cervical mucins........................... 41 
4.5. Cell viability assays .................................................................................................. 42 
4.6. Anti-HIV-1 activity of the crude cervical mucus plugs in the context of cell-free 
virus: Firefly luciferase-based reporter assay .............................................................. 43 
4.7. Anti-HIV-1 activity of the purified cervical mucins in the context of cell-free 
virus: Firefly luciferase-based reporter assay .............................................................. 46 
4.8. Enhancement of SIVmac239 infection by crude cervical mucus plug .................. 47 
4.9. Characterizing the mode of action of the crude cervical mucus plug against 
HIV-1................................................................................................................................... 48 
                                                                                                                
 
 
4.10. -lactamase-Vpr fusion assay in the context of HIV-1YU-2: Crude cervical 
mucus plugs ...................................................................................................................... 50 
4.11. -lactamase-Vpr fusion assay in the context of HIV-1NL4.3: Crude cervical 
mucus plugs ...................................................................................................................... 52 
4.12. -lactamase-Vpr fusion assay in the contexts of HIV-1YU-2 and HIV-1NL4.3: 
Purified cervical mucins ................................................................................................... 54 
4.13. Anti-HIV-1 activity of the crude cervical mucins in the context of cell-
associated virus ................................................................................................................ 55 
4.14. Anti-HIV-1 activity of the crude cervical mucus plugs in the context of cell-
free virus: GFP-based reporter assays ......................................................................... 57 
Chapter – 5: Discussion ................................................................................................... 59 
Chapter – 6: Conclusion................................................................................................... 71 
Chapter – 7: Appendices.................................................................................................. 72 
7.1. Consent form ............................................................................................................. 72 
7.2. Patient information sheet ......................................................................................... 73 
7.3. Ethics approval by the University of Cape Town ................................................. 74 
7.4. Ethics approval by the provincial health department of the Eastern Cape...... 75 
7.5. Clinical profiles of the study cohorts: Crude cervical mucus plugs ................... 76 









                                                                                                                
 




AIDS Acquired immunodeficiency syndrome  
ANOVA Analysis of variance 
ARV Antiretroviral 
ATCC American Type Culture Collection 
ATP Adenosine tri-phosphate  
BlaM-Vpr -lactamase-Viral protein 
CC Cell control 
CCR5 C-C chemokine receptor type 5 
cm Centimetre 
CMP Cervical mucus plug 
CO2 Carbon dioxide 
CsCl Caesium chloride 
CXCR2 C-X-C chemokine receptor type 2 
CXCR4 C-X-C chemokine receptor type 4 
CYS Cysteine 
Da Dalton 
DMEM Dulbecco’s modified eagle’s medium 
DNA Deoxyribonucleic acid 
E. coli Escherichia coli 
EC Eastern cape  
                                                                                                                
 
2 | P a g e  
 
EDTA Ethylenediaminetetraacetic acid 
FACS Fluorescent activated cell sorting  
Fig. Figure 
FSC-A Forward scatter-area 
FSC-H Forward scatter-height 
SSC-H Side scatter-height 
FRT Female reproductive tract 
GFP Green fluorescent protein 
GIT Gastrointestinal tract 
GuHCl Guanidine hydrochloride  
HAART Highly active antiretroviral therapy  
HCl Hydrochloric acid 
HEK293T cells Human embryonic kidney 293 cells with large SV40 T 
antigen 
H.F. Verwoed Hospital Hendricks Frensch Verwoed hospital 
HIV Human immunodeficiency virus 
HMGN2 Highly-mobility group nucleosomal-binding domain 2 
HTLV-lll Human T-lymphotropic virus lll 
HREC/REF Human research ethics committee/Reference  
IgA Immunoglobulin A 
IgG Immunoglobulin G 
kDa Kilodalton 
L Litre 
                                                                                                                
 
3 | P a g e  
 
LAV Lymphadenopathy-associated virus 
M Molar 
mA Milliamps  
mBa Millibars 
MDa Megadaltons 
mg/ml Milligram per millilitre  
MGH Mthatha General Hospital 
ml Millilitre  
mM Millimolar  
mm3 Cubic millimetre  
MMP Matrix metalloproteinase 
mRNA Messenger ribonucleic acid 
NaCl Sodium chloride 
NaN3 Sodium azide 
Na2S2O5 Sodium metabisulphite  
NBT/BCIP Nitro-blue tetrazolium and 5-bromo-4-chloro-3-
indolyphosphate  
NEM N-ethylmaleimide  
NIH National Health Institute 
N Normal 
p Plasmid 
PAS Periodic acid Schiff 
PBS Phosphate buffer saline 
                                                                                                                
 
4 | P a g e  
 
PBST Phosphate buffered saline Tween 20 
PFA Paraformaldehyde 
PMSF Phenylmethanesulfonyl fluoride  
RLU Relative light units 
RNA Ribonucleic acid  
rpm Revolution per minute 
RPMI 1640 Roswell park memorial institute 1640 
RSV Respiratory syncytium virus  
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel     
electrophoresis 
SEM Standard error of the mean  
SIV Simian immunodeficiency virus 
SLPI Secretory leukocyte protease inhibitor 
TIF Tagged image file 
TIMP Tissue inhibitor of metalloproteinase  
UNAIDS Joint United Nations Programme on HIV and AIDS 
USA United States of America 
UTI Urinary tract infection 
v Version 
V Volt 
VC Virus control 
V0 Exclusion volume 
Vi Inclusion volume 
                                                                                                                
 
5 | P a g e  
 
vWF von Willebrand factor 
g/ml Microgram per millilitre  
g Microgram 
l Microliter 








C Degrees Celsius  
 Micro 









                                                                                                                
 
6 | P a g e  
 




The first documented clinical accounts of Acquired Immunodeficiency Syndrome 
(AIDS) were reported in 1981 in Los Angeles, the United States of America (USA), 
when the clinicians recognized a group of five homosexual males who presented 
with rare pneumonias that were associated with immunodeficiency [1]. In 1982, 
similar reports emerged from several European countries [2-4]. Ugandan doctors in 
the Kasensero village recognized a new disease that predominantly affected 
heterosexuals. This disease was accompanied by weight loss and diarrhoea, 
acquiring the name of “slim disease”, given to it by the locals [5]. In 1983, the South 
African doctors at H.F. Verwoerd hospital reported two cases of flight steward 
homosexual males, who had travelled to the USA and upon their return, presented 
with opportunistic infections that were associated with immunodeficiency [6]. 
 
The group of Luc Montagnier isolated a retrovirus called Lymphadenopathy 
Associated Virus (LAV) [7] whilst that of Robert Gallo isolated another retrovirus, 
which they called human T-lymphotropic retrovirus (HTLV-lll) [8]. Molecular evidence 
emerged that LAV and HTLV-lll were identical and both caused AIDS [9-11]. This 
prompted the International Committee on the Taxonomy of Viruses to group these 
viruses under one name: Human Immunodeficiency Virus (HIV). By late 1985, the 
AIDS wave had swept across the world, and ten years later, HIV had infected about 
14 million people globally [12, 13]. In 1996, the United Nations established a Joint 
United Nations Programme on AIDS (UNAIDS) to spearhead a global action against 
the HIV/AIDS pandemic [14].  
 
After several efforts to contain the HIV/AIDS pandemic since its outbreak, the 
UNAIDS recently reported a sharp decline in HIV/AIDS-related deaths between 2000 
and 2016, which are more pronounced among women compared to men [15]. The 
less likelihood of men seeking medical attention compared to women corroborates 
this trend, at least in the context of sub-Saharan Africa [16]. The upscaling of the 
anti-retroviral therapy (ARVs) has significantly suppressed paediatric HIV infections 
globally [15]. 
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Eastern and Southern Africa have seen the steepest decline in new HIV infections 
between 2010 and 2016, which the UNAIDS attributes to the upscaling of the ARV 
therapy in these two regions, where approximately 76% of people are HIV positive 
and 60% of whom are on ARV treatment [15]. Eastern Europe and central Asia have 
seen a 60% rise in new HIV infections between 1990 and 2016 [15]. In Europe, this 
trend correlates with decreasing condom use by the men who have sex with men, a 
population that is 24 times more likely to acquire HIV infection than the general male 
population [16].  
 
There are about 5000 new HIV infections per day in the world and 64% of them 
happen in the sub-Saharan Africa. Of these daily 5000 new HIV infections, 4500 
occur in young adults, 43% of whom are women [15]. In the sub-Saharan Africa, 
young women of child-bearing age still remain at high risk of HIV infection, while in 
the low-prevalence regions HIV infections are more pronounced among the key 
groups: drug users, transgender individuals, prisoners and sex workers. South Africa 
still remains the worst affected country in the sub-Saharan Africa, despite her 
decreasing new HIV infections [15]. These declines are attributed to the South 
African ARV therapy programme, which was launched in 2004 through the public 
health system under the initial guidance of a Comprehensive Care Management and 
Treatment Programme, which was succeeded in 2007 by the National Strategic Plan 
[17]. 
 
The new HIV infections are declining faster among women compared to men, but 
women still account for 59% of the HIV positive people in the sub-Saharan Africa 
[18]. HIV infections are predominantly established through exposure of the mucosal 
surfaces, which are the internal tracts of the body that are in direct contact with the 
outside world and portals of entry for several pathogens that cause human diseases. 
Of these mucosal tracts, HIV transmission is more pronounced in the rectum and 
genital tracts among sexually active individuals [19]. The paediatric infections occur 
in utero, intrapartum and in the postpartum period [20, 21]. 
 
The mode of HIV transmission was unknown until its isolation from the seminal fluid 
and saliva, which pointed towards the possibility of its mucosal transmission [22-24]. 
In line with these findings, Zeigler et al. [25] reported the first case of mother-to-child 
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transmission through breastfeeding. But several lines of evidence opposed the 
possibility of salivary-mediated HIV transmission [26-29]. Supporting these lines of 
evidence, Fultz et al [30], using two chimpanzees, showed that HIV only established 
systemic infection after its application on the vaginal mucosa but not on the oral 
mucosa, even after two rounds of oral application. The authors argued that HIV 
infection of the vaginal mucosa was independent of the vaginal trauma, given the 
absence of blood stains on the swabs following viral application. This suggested 
differences between these mucosae and the well-recognized capabilities of HIV to 
invade the intact mucosae of the ecto-cervix and endo-cervix respectively [31]. 
 
Sexual transmission of HIV is the main driving force behind the HIV/AIDS pandemic 
[32, 33]. To realize the UNAIDS-proposed 2030 Target [18], part of our strategy 
should be to invest more efforts to find alternative ways of blocking HIV transmission 
during sexual intercourse, without ignoring other potential routes of transmission. 
The low probability of HIV acquisition per coital act is suggestive of the active 
presence of anti-viral factors in the female reproductive tract [34]. Habte et al [35] 
reported the inhibition of HIV-1 infection by mucus glycoproteins (mucins), which 
they isolated from the crude mucus plugs of women in labour, just prior to delivery. 
Interestingly, the crude cervical mucus plugs did not inhibit HIV-1 infection in vitro 
[35].   
 
Gosh et al [36] reported the inhibition of HIV infection by the cervico-vaginal lavage 
samples collected from HIV negative and HIV positive women. Cervico-vaginal 
secretions collected from non-pregnant and pregnant women also inhibited HIV 
infection, irrespective of the viral tropism [37]. Cervico-vaginal mucus hindered the 
diffusion of HIV strains [38]. The protonated lactic acid in the human cervico-vaginal 
fluid, which is secreted by the lactobacilli species residing in the vaginal canal, 
inhibited HIV infection in ex vivo experiments [39]. Together, these data suggest the 
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1.2. General overview of the mucus and mucosal tracts 
 
Mucus is an adherent and viscous fluid that is secreted by epithelial cells and 
mucosal glands at the mucosal surfaces of the body, where it protects against 
pathogens, toxic insults and desiccation [40]. Depending on the mucosal surface and 
species, mucus predominantly contains water (~95%), mucins, proteoglycans, non-
mucin proteins, inorganic salts, DNA, lipids and cell debris [41, 42]. The mucus is 
conserved across different species, ranging from amphibians to high order mammals 
[43]. Mucins are large and heavily O-glycosylated proteins with a molecular weight 
range of 0.5 – 20 MDa [40]. They exhibit a specific expression pattern across 
different mucosae of the human body [43], and are the major components of the 
mucus. The evolutionary origin of mucins dates back to as far as metazoan, with five 
to six gel-forming MUC genes conserved across vertebrates, except Xenopus 
tropicalis, which has a panel of 26 gel-forming mucins [44]. 
 
Mucus is involved in several functions across different mucosae and species. 
Gastropods crawl across surfaces of different textures by coating themselves with 
mucus to adhere to these surfaces without contacting them, after which they propel 
themselves over this mucus layer in a process called adhesive locomotion [45]. 
While allowing gaseous exchange and that of other vital molecules, mucus on the 
fish skin must protect against pathogens and toxins in the marine environment [46]. 
A group of marine creatures called mucus-mesh grazers use their mucus meshes as 
a fishing net to capture microscopic particles on which they feed [47]. In humans, the 
mucus coats the internal body tracts, where it acts on the front line of the innate 
immune system. These internal body tracts are broadly classified as oculo-rhino-
otolaryngeal, gastrointestinal, respiratory, and genitourinary tracts respectively. The 
concept behind the mucus barrier functions stems from several studies reporting on 
the changes in mucus production in response to infections [48-51]. 
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1.2.1. Oculo-rhino-otolaryngeal tract 
 
The oculo-rhino-otolaryngeal tract encompasses the eyes, nose, ears and larynx. 
The typical mucosal disorders of this tract include dry eye syndrome, rhino-sinusitis, 
otitis media, and laryngitis; with differential expression of the mucins as a hallmark. 
The mucus layer that covers the ocular epithelium contains MUC2, MUC5AC, 
MUC5B and MUC19; with MUC1, MUC4, MUC16 and MUC20 forming the 
glycocalyx [52]. These mucins are produced by the lacrimal gland, cornea and 
conjunctiva of the eye to maintain homeostasis in the ocular epithelium [53]. 
Abnormalities in the tear film of the eye, for which mucins are the crucial 
components, mediate dry eye syndrome: a feeling of dryness and foreign body 
sensation in the eyes [52]. 
  
The mucus overproduction and goblet cell hyperplasia in the sino-nasal surface are 
the hallmarks of chronic rhino-sinusitis. The normal nasal mucus predominantly 
contains MUC2 and MUC5B, while the sinus mucus predominantly contains 
MUC5AC and MUC5B [54]. Ali et al [54] found the downregulation of MUC2 and 
upregulation of MUC5AC in the sinus mucus of patients with chronic rhino-sinusitis. 
The maxillary mucosa of the patients with chronic rhino-sinusitis showed elevated 
mRNA and protein levels of MUC5AC and MUC5B respectively [55]. The mRNA 
levels of MUC4, MUC5AC, MUC5B, MUC7 and MUC8 were upregulated in the sinus 
mucosa of patients with chronic rhino-sinusitis [56]. Together, these data highlight 
the modification of mucus components in chronic rhino-sinusitis. 
 
Chronic otitis media is a leading cause of hearing loss among children and accounts 
for a high proportion of annual paediatric clinical visits in the USA [57, 58]. Its 
symptoms include accumulation of thick mucus in the middle ear cavity, which is 
dominated by MUC5B [59]. Preciado et al [59] noticed occasional upregulation of 
MUC5AC in patients with chronic otitis media. After challenging the mouse middle 
ear epithelial cells with Haemophilus Influenza, Val et al [60] found that Muc5ac acts 
as an acute responder during ear infection while Muc5b acts as a chronic responder. 
Of the membrane-bound mucins, MUC1 and MUC4 are also upregulated during ear 
infection [61]. These changes in MUC gene expression levels could be used to 
monitor the patient response to treatment in the clinical settings [62].  
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Laryngopharyngeal reflux, a backward flow of the corrosive gastric content up the 
oesophagus into the laryngopharynx, is a common cause of laryngitis that accounts 
for up to 50% of the voice disorders [63]. The mucosal barrier in the larynx is 
organized around a panel of mucins as discussed elsewhere [64]. The expression 
levels of MUC2, MUC3, MUC5AC and MUC5B were reduced in patients with 
laryngopharyngeal reflux-mediated laryngeal injury [64]. Given that MUC3 is a 
membrane-bound mucin, this shows that not only does the gastric refluxate disrupts 
the mucus layer covering the laryngeal epithelium, but also the underlying 
glycocalyx, thereby compromising MUC3-mediated restoration of the laryngeal 
epithelium after injury [65]. 
 
1.2.2. Respiratory tract 
 
The respiratory tract mucus, which is in constant motion by muco-ciliary transport, is 
organized around MUC5AC and MUC5B as the structural components [66]. The 
muco-ciliary transport and alveolar macrophages in the lungs facilitate the pathogen 
clearance and maintain homeostasis [67]. The lung mucus layer is packed on top of 
the periciliary liquid layer to facilitate ciliary beating that clears the entrapped 
pathogens [68]. The membrane-bound mucins (MUC1, MUC4, MUC16) attached to 
the underlying epithelial cells are embedded into the periciliary liquid layer along with 
cilia to block the escaping foreign objects from reaching the underlying epithelial 
cells [69].  
 
Of these two gel-forming mucins in the lung mucus, evidence from the knockout 
studies in mice attribute muco-ciliary clearance to Muc5b [70, 71]. Overexpression of 
Muc5ac protected the mice against influenza infection, while the Muc5ac-/- mice 
showed effective muco-ciliary clearance [70]. The Muc5b-/- mice had reduced muco-
ciliary clearance compared to the wild type mice following the bacterial infection to 
which they later succumbed [71]. Together, these data highlight the different roles 
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1.2.3. Gastrointestinal tract 
 
The gastrointestinal tract (GIT) is a tubular structure that stretches from the mouth to 
the rectum, with varying specializations in the form of organs, which are constantly 
exposed to foreign and commensal pathogens [72]. The mucosa of the GIT is 
covered by the mucus, which is produced by the glands and epithelium lining its 
tract. The salivary glands in the mouth produce 1.2-1.5 L of saliva per day, which 
contains MUC5B and MUC7: the secreted mucins that lubricate the oral cavity and 
the ingested food [73, 74]. Being home to over 700 commensal bacteria, saliva 
ensures that these commensal bacteria live in harmony with the oral cavity, while 
protecting the oral mucosa against colonization by the foreign pathogens [74, 75].  
 
In the stomach, mucus protects the epithelium against the corrosive effect of pepsin 
and hydrochloric acid (pH 1-2) during digestion, which are secreted by the mucosal 
glands [76]. The underlying epithelial cells secrete bicarbonate to create a pH 
gradient that maintains a neutral pH at the cell surfaces [76]. The crude mucus gel 
lining the stomach epithelium is organized into two layers that predominantly contain 
extended sheets of MUC5AC, which are interspersed with MUC6 [77]. The loosely-
packed outer layer is an ecological niche for microbiota and lubricates transiting 
stomach content, while the regenerative inner layer is tightly-packed to protect the 
epithelium against toxic and pathogen insults [78, 79]. 
          
Unlike in the stomach, a single layer of loosely-packed mucus that is organized 
around MUC2 protects the intestinal epithelium [80]. In addition to protection, mucus 
in the intestines facilitates a smooth passage of the nutrients during absorption while 
excluding microbe populations [80]. Mucus undergoes a constant turnover to limit 
exposure to the virulent pathogens [72]. The Paneth cells secrete antibacterial 
peptides to facilitate microbial clearance in the intestinal mucus [81]. The 
unabsorbed waste material from the intestines transits into the colon in preparation 
for excretion. The colonic mucosa is covered by a double layer of mucus that is 
organized around MUC2 [82]. The loose outer mucus layer is an ecological niche for 
the microbiota, while the regenerative and tightly-packed inner mucus layer protects 
the epithelium [72]. How the same MUC2 behaves differently between the intestines 
and colon remains a mystery, which highlights the different characteristics exhibited 
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by the cellular machineries of the goblet cells lining these two regions. It could also 
be that the commensal bacterial products in the colon, e.g. lactic acid [83], which are 
almost absent in the small intestines, mediate the differences in MUC2 gelation.    
 
1.2.4. Genitourinary tract 
 
The genitourinary tract encompasses the urinary tract and reproductive tract 
respectively. The mucosa of the normal kidneys in the urinary tract is predominately 
made up of MUC1, while MUC3 dominates in neoplasia [84]. Kirby et al [85] reported 
a frameshift mutation in MUC1 as a cause of autosomal dominant tubulo-interstitial 
kidney disease, shortly known as Mucin 1 Kidney Disease, which is the hereditary 
chronic nephropathy and risk factor of kidney failure. Nie et al [86] found that MUC1 
facilitates renal calcium re-absorption in the distal convoluted tubules of the kidney, 
thereby protecting against nephrolithiasis, which is caused by impaired calcium re-
absorption [87]. These data highlight an active role of MUC1 in the renal physiology. 
 
The bladder stores urine, which carries toxins that could not be re-absorbed by the 
kidneys. This requires the bladder to protect its mucosa from potential toxin insults 
and pathogen invasion. The normal bladder epithelium consists of MUC1 and MUC4 
[88-90]. Parsons et al [91], reported the antibacterial activity of a surface mucin lining 
the epithelium of the rabbit and human bladders. They found that this muco-
polysaccharide layer would be disrupted by acid treatment, re-synthesized in less 
than 24 hours and replenished in about 48 hours, thereby supporting a well-
recognized mucus turnover [92, 93]. Rigorous studies are lacking that investigate the 
direct role of the mucins in biofilm formation during urinary tract infection [94].  
 
In the reproductive tract, a repertoire of mucins protects the epithelium against 
pathogens, and mechanical and chemical insults, while ensuring a smooth process 
of reproduction in both males and females [95, 96]. The mucins exhibit a unique 
expression pattern across different organs of the male reproductive tract, reflecting 
different specialities within this tract [95]. The female reproductive tract is covered by 
the mucus layer that is organized around a repertoire of mucins [96], and provide a 
barrier against pathogens. The secretions of the female reproductive tract protect 
against a repertoire of pathogens that cause human diseases [36-39, 97, 98]. 
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1.3. Cervical mucus and the mucus plug 
 
Cervical mucus is a heterogeneous and viscous secretion that is secreted by the 
mucosal cells and glands lining the epithelium of the endo-cervix [99]. It coats the 
epithelia of the female reproductive tract (FRT), where it predominantly protects 
against desiccation and invading pathogens. The mucus in the FRT operates under 
control of the steroid hormones (oestrogen and progesterone), which change the 
mucus rheology to meet the demands of the FRT [100]. The FRT must protect its 
epithelia against invading pathogens while tolerating the foreign spermatozoa and 
the foetal allograft on its endometrium, whose cells may persist in the maternal blood 
for decades due to foeto-maternal micro-chimerism [101].  
 
The cervical mucus contains MUC5AC, MUC5B and MUC6 as its gel-forming 
mucins, while MUC1, MUC4 and MUC16 form the glycocalyx in the FRT [96, 102]. 
There are contrasting data on the expression of MUC2 in the human endo-cervix, 
with more evidence opposing its expression [35, 96, 100, 102, 103]. There is 
inconsistency and poor signals of MUC2 expression even in the data that support its 
expression, thereby making it difficult to recognize MUC2 as an endo-cervical mucin 
[35, 103]. Of the recognized cervical mucins, MUC5B is the major gel-forming mucin 
in the endo-cervix that peaks before mid-cycle, while MUC4 dominates the 
glycocalyx among the membrane-bound mucins [104].  
 
During the oestrogen-dominated follicular phase of the menstrual cycle, cervical 
mucus becomes less viscous to allow sperm penetration. It then gets thicker and 
viscous during the progesterone-dominated luteal phase to limit further sperm 
penetration [105]. Pommerenke and Viergiver [106] showed that administered 
progesterone counteracts the effect of oestrogen on the cervical mucus of castrated 
women, who cannot secrete these steroid hormones due to the removal of their 
ovaries. Gipson et al [107] reported that MUC5B levels peak at mid-cycle. This is 
coupled with a 99% increase in water content of the cervical mucus at mid-cycle, 
thereby increasing the mucus volume, which drops to about 91% during the 
progesterone dominated-luteal phase to produce thick cervical mucus [108]. Mucus 
hydration most likely dilutes the biochemical factors that mediate mucin 
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entanglement and increase the mucin pore size to form a more receptive mucus gel 
[42, 109, 110]. MUC5B peaks at mid-cycle presumably to retain more water, thereby 
forming a watery mucus with high sperm receptivity in the endo-cervix [107]. 
  
It is of no doubt that this watery texture of the cervical mucus at mid-cycle is critical 
for sperm-mucus interactions and successful pregnancy. “In the investigation of 
sterility—if we expect to proceed understandingly—we must determine whether the 
secretions of the cervical canal are favourable or not to the vitality of the 
spermatozoa.” said J. Marion Sims in 1868, and about a century and a half later, his 
words still reverberate throughout the field of reproductive biology (adapted from 
Stevenson, 1958 [111, 112]). Stevenson [112] proposed that cervical mucus must 
meet certain requirements for a successful pregnancy: amount, clarity, spinnbarkeit, 
and pH. Existing evidence suggest that cervical mucus protects the spermatozoa 
from phagocytosis in the FRT and facilitate their movement to the uterus to ensure 
successful fertilization [113, 114]. Together, these data highlight the role played by 
the cervical mucus in pregnancy regulation. 
 
As early as mid-1940s, it became clear that not only does cervical mucus facilitates 
pregnancy and protects against desiccation, but also protects against genital tract 
infections. Koch [115] reported that cervical cultures were more likely to be negative 
for Neisseria gonorrhoea during the luteal phase and positive during the oestrogen-
dominated follicular phase when mucus becomes watery and more alkaline. 
Moriyama et al [116] reported the presence of secretory leukocyte protease inhibitor 
(SLPI) in the cervical mucus of women at mid-cycle. Eggert-Kruse et al [98] reported 
the antimicrobial activity of the cervical mucus collected from sexually active women 
at mid-cycle. Ming et al [97] purified and characterized antimicrobial activity of the 
two antimicrobial factors (HMGN2 and SLPI) from the human cervical mucus 
samples, thereby highlighting the antimicrobial activity of the cervical mucus.    
    
During pregnancy, the body of a mother-to-be undergoes physiological changes 
predominantly to maintain pregnancy till term [117-121]. Among these changes is a 
cervical remodelling that includes transformation of cervical mucus into a thick solid 
material called cervical mucus plug (CMP) as the progesterone levels begin to rise 
[122], and while bacterial load is increasing in the neighbouring vaginal canal [123]. 
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These changes in cervical mucus during pregnancy were initially recognized in 1948, 
when Atkinson et al [124] reported an increased production of the cervical mucins by 
pregnant women. The CMP (10 g) must tightly seal the cervical os during the 
course of pregnancy to prevent bacterial ascent from the vaginal canal into the 
cervix, failure of which may cause pre-term deliveries that are responsible for 
approximately 35% of the global annual neonatal mortalities [125].  
 
At term, when a purpose of CMP is served, cervix sheds off the CMP to allow 
parturition. The cervix releases the CMP (in part) through a controlled action of 
matrix metalloproteinases (MMPs), a group of proteolytic enzymes that degrade 
extracellular matrix in the rigid cervix, thereby triggering cervical dilatation [126] and 
foetal membrane rupture [127]. The cervix maintains a balance between the MMPs 
and tissue inhibitors of metalloproteinases (TIMPs). This balance shifts in favour of 
the TIMPs during pregnancy to suppress MMPs and prevent pre-term membrane 
rupture, and then shift in favour of the MMPs at term to allow the process of 
parturition [128]. These MMPs and TIMPs are components of the CMP itself, 
highlighting its capabilities to remodel the same tissue in which it resides.   
 
1.4. Mucins  
 
Mucins are a group of heavily O-glycosylated proteins with a molecular weight range 
of 0.5 – 20 MDa [40], which are synthesized by the mucosal cells and glands lining 
the mucosal surfaces of the body. They exhibit extensive O-glycosylation and to a 
lesser extent, N-glycosylation and the still controversial C-mannosylation, which 
together contribute about 80% to an overall molecular weight of the mucins [43]. 
Mucins have evolved to become a family of 20 members [129], and are grouped on 
the basis of heavily O-glycosylated tandem repeat domains (http://www.hugo-
international.org/hugo/). Mucins are encoded by a group of genes called MUC 
genes, which have been mapped on several chromosomes across the human 
genome [129]. The mucins are designated MUC, followed by a number according to 
the order of discovery—MUC1 in humans and Muc1 in animals. They exhibit a 
specific expression pattern across the human mucosae to meet the specific needs of 
a particular mucosa (Fig. 1). 
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Figure 1: The expression pattern of the gel-forming mucins under normal 
conditions. Illustration of a constitutive expression profile of the gel-forming mucins 
across different mucosae of a healthy person. The blue-coloured mucins have CYS 
domains interspersing the mucin domains along their protein backbones while the 
purple-coloured mucins do not. The font size represents a degree of expression for 
each mucin in a particular mucosa (with permission of Elsevier, adapted from 
Demouveaux et al [43]).   
 
Mucins are broadly divided into two groups: secreted and membrane-bound mucins. 
Secreted mucins are further subdivided into gel-forming and non-gel-forming mucins. 
Of these 20 mucins, five mucins—MUC2, MUC5AC, MUC5B, MUC6 and MUC19—
can polymerize through their terminal ends and retain water molecules through their 
hydrophilic glycans or oligosaccharide side chains, to form mucus gels that coat the 
mucosal surfaces of the body, thus referred to as the gel-forming mucins [129]. 
MUC7, MUC8 and MUC9 are secreted non-gel-forming mucins, because they do not 
polymerize and participate in mucus gelation [129]. The remaining ten mucins are 
attached to the membranes of the epithelial cells where they form the glycocalyx just 
underneath the mucus layer [129], hence referred to as membrane-bound mucins. 
The membrane-bound mucins—MUC1, MUC3A/B, MUC4, MUC12, MUC13, 
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MUC15, MUC16, MUC17, MUC19, MUC20 and MUC21—predominantly serve to 
prevent toxin penetration and pathogen adherence to the underlying epithelial cells 
[130], and engage in molecular signalling to trigger several biological processes, a 
phenomenon that is well-characterized in cancer biology [131].  
 
Of this repertoire of mucins, the endo-cervix expresses MUC5AC, MUC5B and 
MUC6 as its gel-forming mucins while MUC2 expression remains controversial [96, 
100, 103]. MUC1, MUC4 and MUC16 are the membrane-bound mucins expressed 
by the endo-cervix [100, 102]. MUC2, MUC5AC, MUC5B and MUC6 genes are 
clustered within a ~400 kb region found on the short arm of chromosome 11p15.5, 
with highly conserved exon-intron boundaries and amino acid terminal sequences 
flanking their large central mucin domains [132, 133]. Unlike other gel-forming 
mucins, MUC19 is found on chromosome 12q12 [134]. Genes encoding the 
membrane-bound mucins in the endo-cervix are located in different chromosomes 
across the human genome: MUC1 on chromosome 1q21, MUC4 on chromosome 
3q29 and MUC16 on chromosome 19p13.2 respectively [129]. 
 
1.4.1. Secreted gel-forming mucins 
 
The gel-forming mucins share several structural features, which are characterized by 
a large and heavily O-glycosylated central region that is flanked by naked N and C-
terminal regions, thereby forming a bottle-brush like structure [40]. This large central 
region has a high content of tandemly repeated proline, threonine and serine amino 
acid residues to constitute PTS pattern, with threonine and serine acting as glycan 
acceptors to form extensively O-glycosylated mucin domains [135, 136]. These 
mucin domains are interspersed by short invariant cysteine domains (CYS)—except 
for MUC6 and MUC19—that are believed to non-covalently cross-link the mucin 
polymers through intramolecular disulphide bonds and determine mucus pore size 
[137]. The tandemly repeated sequences that encode the mucin domains differ in 
length and sequence for each mucin, with varying number of tandem repeats 
between and within individuals to constitute polymorphism, except for MUC5B [138]. 
Terminal regions of the gel-forming mucins resemble von Willebrand factor (vWF), a 
blood-clotting glycoprotein. Their N-terminal region consists of cysteine-rich domains 
called D1, D2, D’ and D3 housed within a vWF-like domain. The C-terminal region 
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consists of cysteine-rich domains called D4, B, C domains and cysteine knot within 
another flanking vWF-like domain [129]. In the C-terminal region, MUC6 has a 
cysteine knot only and lacks vWF-like domain, while MUC19 has only C domain and 
cysteine knot [43, 134]. Evidence from the studies on recombinant mucins shows 
that the gel-forming mucin polymerize through their flanking vWF-like domains found 
on the terminal ends and cross link to form mucus gels [109]. 
 
1.4.2. Secreted non-gel-forming mucins 
 
The secreted non-gel-forming mucins include MUC7, MUC8 and MUC9 [129]. These 
mucins do not polymerise and form gels, because neither of them has the vWF-like 
domains at their terminal ends. MUC7 is located on chromosome 4q13.3, carries 23 
tandem repeat amino acids in its central mucin domain. It is expressed by the 
sublingual and submandibular glands in the mouth, and by the submucosal glands in 
the respiratory tract respectively [129, 139]. MUC8 is located on chromosome 
12q24.3, carries about 13/14 tandem repeat amino acids in its central mucin domain 
and expressed by the submucosal glands in the respiratory tract [129], with less 
characterized expression across the FRT [140]. MUC9 is located on chromosome 
1p13, with a central mucin domain of 15 tandemly repeated amino acids and 
expressed in the oviduct [141]. The salivary MUC7 is the most characterized mucin 
among the secreted non-gel-forming mucins, through its active role in microbial 
clearance in the oral mucosa [142-144]. There is little information about the role of 
MUC8 in the respiratory tract mucus, and MUC9 is believed to protect the early 
embryo in the oviduct and the oviduct itself against pathogen invasion [141].          
 
1.4.3. Membrane-bound mucins 
 
The membrane-bound mucins also do not polymerize and form gels, since they lack 
the vWF-like domains in their terminal ends. Instead, they have a transmembrane 
domain, hence found attached at the surfaces of the epithelia cells where they form 
a glycocalyx together with other glyco-conjugates [130]. However, to a lesser extent, 
the membrane-bound mucins contribute to the mucin content of the mucus through 
their heavily O-glycosylated extracellular domain, which can be cleaved from the cell 
membranes by the sheddases, a group of proteolytic enzymes that mediate 
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shedding of the membrane-bound proteins, or directly secreted into the mucus 
through alternative splicing [145-147]. They are characterized by a large heavily O-
glycosylated N-terminus (-subunit) and short naked C-terminus (-subunit). Of the 
endo-cervical membrane-bound mucins, in addition to its terminal ends, MUC1 has a 
sea urchin sperm protein enterokinase agrin (SEA) domain located between the end 
of the O-glycosylated -subunit and its transmembrane domain, while MUC16 has 
several SEA domains [131]. MUC4 lacks SEA domains, but has the nidogen (NIDO), 
adhesion-associated domain in MUC4 and other proteins (AMOP) and von 
Willebrand factor type D (vWD) (NIDO-AMOP-vWD) domains with three epidermal 
growth factor (EGF)-like domains [131]. Generally, the SEA domains serve as the 
unifying feature for the membrane-bound mucins, except for MUC4 that evolved from 
a different ancestor, at least when compared to MUC1 and MUC16 [148]. These 
SEA domains serve as the cleavage sites on which the sheddases must act in order 
to release the -subunits of these mucins, while MUC4 is cleaved behind its vWD 
domain [131]. A mutation in the SEA sequence inhibits the shedding of MUC1 [149]. 
 
1.4.4. Structural models of gel-forming mucins 
 
Two models of mucin structure and conformation have been proposed based on the 
use of different extraction procedures [150, 151]. Allen and Snary proposed the 
windmill model (Fig. 2A) after isolating the mucins from the pig gastric mucus, which 
they collected in 0.2 M NaCl and 0.02% NaN3 without protease inhibitors. According 
to this model, the four glycosylated mucin subunits of 2x106 Da are inter-linked 
through a naked ‘linker’ protein of 7x104 Da at the C-termini, through disulphide 
bonds, producing a windmill structure [150, 152]. Carlstedt and Sheehan isolated the 
mucins from the cervical and gastric mucus, which they collected in 6 M GuHCl with 
protease inhibitors and proposed a random coil model [151]. In this model (Fig. 2B), 
the glycosylated mucin subunits are joined end-to-end through the disulphide bonds 
to assume a linear random coil structure [151]. The accepted genetic model of the 
mucin structure supports the model proposed by Carlstedt and Sheehan [151]. The 
MUC genes are characterized by the central tandemly repeated sequences encoding 
the mucin domains that are interspersed by the short invariant cysteine-rich domains 
[40]. This central region is flanked by the 5’ and 3’ regions respectively. The 5’ 
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sequence encodes a vWF-like domain that houses four D-domains while the 3’ 
sequence encodes another vWF-like domain that houses D, B and C domains with a 
cysteine knot [40, 109, 129]. The mucin monomers join end-to-end through their 
cysteine-rich vWF-like domains to form long polymers [109]. 
 
   A                                                                 B 
 
Figure 2: The illustration of the proposed biochemical models of the mucin 
structure. The windmill model (A) shows that the four mucin subunits are inter-
linked by a naked ‘linker’ protein through disulphide bonds. On the other hand, the 
random coil model (B) argues that the mucin subunits are joined end-to-end through 
the disulphide bonds in a random coil fashion (Adapted from Mall, 2008 [153]).   
        
1.5. Aspects of the cervical mucus/plug 
 
The cervical mucus, a heterogeneous and viscous secretion that occludes the 
cervical os must selectively control entry of several organisms into the cervix. It acts 
by blocking access to pathogens while cyclically allowing entry of the spermatozoa to 
facilitate reproduction, failure of which may cause gynaecological and obstetrical 
problems [100, 123]. During pregnancy, it transforms into a solid cervical mucus plug 
that blocks bacterial ascent from the vaginal canal into the cervix until parturition to 
ensure successful pregnancy [154, 155]. The rhythmical effect of the steroid 
hormones changes the mucus rheology and its content, which is largely biochemical 
and immunological in nature [97, 155, 156]. Certain factors may be released from the 
foeto-maternal unit into the cervical mucus/plug during diseases or pregnancy, 
thereby making it a perfect breeding ground for biomarkers to assist in clinical 
diagnosis [157]. 
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1.5.1. Biochemical aspects of the cervical mucus/plug 
 
Cervical mucus must provide the spermatozoa with an environment in which they 
can survive for a period long enough to increase the chances of fertilization. In 1873, 
J. Marion Sims noticed that spermatozoa could survive in the vagina for 12 hours 
and in the cervix for 36 hours [158]. Lamar et al [159] noted that the spermatozoa 
could survive in the cervical mucus longer than they could survive in the seminal 
fluid, suggesting the presence of molecules needed for elongated sperm survival in 
the cervical mucus. It later emerged that the cervical mucus is loaded with glucose, 
glycogen and amylase to catabolise glycogen back into usable glucose, which like 
the fructose capacitates sperm motility [160]. The glucose in the cervical mucus is 
also a basic energy source for the implanted trophoblast in the endometrium [161].  
 
In 1946, Papanicolaou noticed that the cervical mucus samples crystalized when 
viewed under microscope upon drying on a microscope slide [162]. These crystal 
patterns would be well-defined at mid-cycle when oestrogen levels are high and 
diminish post-ovulation and in pregnancy when progesterone has dominated. 
Campos da Paz [163] reported that progesterone inhibits crystallization of the 
cervical mucus. Using X-ray crystallography, Macdonald [164] confirmed these to be 
true crystals that are rich in sodium chloride and potassium chloride, and built around 
tiny amounts of organic material (proteins and carbohydrates) in the cervical mucus. 
 
It is recognized in the GIT that the endogenous lipids are responsible for 
hydrophobicity of the gastric mucus [165]. Breckenridge and Pommerenke [166] 
reported the presence of cholesterol and lipid phosphorus in the cervical mucus 
samples. Singh and Swartwout [167] reported the presence of the hydrocarbons, 
glycerides, cholesterol, fatty acids and phospholipids in the cervical mucus samples 
collected from the two ovulating women. They noticed that the total lipid content of 
the cervical mucus decreased at mid-cycle when the oestrogen was at the peak, 
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1.5.2. Immunological aspects of the cervical mucus/plug 
 
The FRT must maintain immunity against foreign pathogens while tolerating the 
foreign spermatozoa and developing foetus. Safaeian et al [168] reported the low 
levels of IgA and IgG in the cervical mucus collected from women at mid-cycle. A 
comparison between these two immunoglobulins showed more decline of the IgG 
levels compared to the IgA levels in the cervico-vaginal secretions collected from 
ovulating women at mid-cycle [169]. Another study in rhesus macaques at mid-cycle 
showed the decreased immunoglobulin levels in the cervical mucus [170]. Antibody 
screening in the cervico-vaginal secretions of 45 infertile women attending Kammal 
El-Sammrari Hospital in Iraq showed a 62% increase of anti-sperm antibodies 
among infertile women compared to 3.3% from fertile women [171]. Together, these 
data suggest that the cervical mucus must lower its immune defences to tolerate the 
spermatozoa during the receptive phase of the menstrual cycle. 
  
During pregnancy, the FRT remains under the control of progesterone and this 
means a slow production of the dehydrated mucus plug with impaired turnover, 
thereby maximising exposure to the virulent pathogens [93]. We have learned from 
the mucosal biology of the respiratory tract in cystic fibrosis patients that the mucus 
plug impairs mucus turnover and predisposes to infections by the entrapped 
pathogens [69], a circumstance that would yield severe obstetrical problems in the 
cervix. Unlike in the respiratory tract, the mucus plug in the cervix retains more 
phagocytes to ensure continuous clearance of entrapped pathogens in the face of 
the impaired mucus turnover [155].  
 
Hein et al [155] showed elevated levels of intact immunoglobulins and phagocytes in 
the cervical mucus plugs collected from women in labour when compared to the 
cervical mucus collected from ovulating non-pregnant women. Hordes et al [172] 
reported a median IgG:IgA ratio of 6:1 in the cervical mucus plugs collected from 
pregnant women in their second trimester of gestation. Proteomic studies showed an 
abundance of immunological factors in the cervical mucus plugs collected from 
women in labour when compared to the cervical secretions collected from non-
pregnant women [121, 173]. Vornhagen et al [174] reported that when overwhelmed 
by the pathogens, the cervical mucus plug components can stimulate leukocytes in 
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the systemic blood to activate a complement system and destroy the invading 
pathogens. Together, these studies show a synergy between the innate and 
adaptive immune responses in the cervical mucus plugs to deliver good health 
outcomes for the mothers and their babies, while saving them from the economic 
burden of pregnancy complications that require frequent clinical visits [175, 176].        
 
1.5.3. Clinical aspects of the cervical mucus/plug 
 
The cervical secretions can retain a repertoire of biologically active factors from the 
systemic circulation and their surroundings [157, 174]. In addition to their 
biochemical and immunological nature, these secretions can be a fertile field from 
which we can harvest the biomarkers of clinical relevance and learn about the 
changes in the FRT to facilitate diagnosis. The fern pattern assumed by the cervical 
mucus upon drying on a microscope slide due to mucus crystallization in response to 
the fluctuating steroid hormones in the FRT, could be used to monitor functionality of 
the corpus luteum [177]. Maxwell Rowland [178] used a fern test to determine the 
oestrogen activity, ovulation and early pregnancy from the cervical mucus samples. 
A well-defined fern pattern from the cervical mucus of a woman in menopause 
indicates oestrogen activity and can alert the attending clinician about a possible use 
of oestrogen therapy or the presence of an oestrogen-secreting tumour [164].  
 
A proteomic study reported nine downregulated proteins in the cervical mucus of 
women with endometriosis when compared to the normal women [179]. The authors 
noticed that other 15 proteins were exclusively expressed in the normal cervical 
mucus and absent in the endometriosis cervical mucus. This points towards the 
cervical mucus as a potential source of biomarkers for the diagnosis of 
endometriosis. Until day 7 of the menstrual cycle, MUC1 showed low but detectable 
signals in the uterine flushing of fertile women, after which the signals drastically 
increased and peaked at day 13, suggesting the loss of MUC1 by the uterine 
epithelium [180]. Women who had spontaneous miscarriages showed low signals of 
MUC1 throughout the cycle, a possible retention of MUC1 by the uterine epithelium 
and impairment of trophoblast’s implantation [181]. These data suggest that levels of 
MUC1 in the uterine flushing could be used to predict the window of implantation 
among women of the reproductive age to improve fertility.  
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The foetal cells can migrate from the placenta into the maternal organs through a 
process called foeto-maternal cellular trafficking, which was first documented in 1893 
by a German pathologist Christian Georg Schmorl after he found clumps of foetal 
cells in the lungs of eclamptic women on whom he performed autopsies [182]. 
Shettles hypothesized that the same trophoblasts could be shed from the regressing 
chorionic villi and leak into the cervical mucus plug during pregnancy. In 1971, he 
collected trophoblasts from the cervical mucus plugs of 30 pregnant women in their 
early pregnancy from which he accurately diagnosed the sexes of 10 foetuses using 
Y-chromosome fluorescein dye that is positive for a male foetus [157]. Mantzaris et 
al [183] extended these observations using a multiplex fluorescent polymerase chain 
reaction in prenatal diagnosis on the trophoblasts isolated from the cervical mucus 
plugs of 22 pregnant women in their early pregnancy, and accurately diagnosed the 
sexes of 22 foetuses. The cervical mucus plug could be used in prenatal diagnosis 
as an alternative method to the invasive amniocentesis and chorionic villous 
sampling, which carry a miscarriage risk of 0.5-1% and 5% rate of false-positive 
results respectively [184, 185].                       
  
1.6. The antimicrobial activities of the cervical mucins 
 
The purified salivary MUC5B acts as an anti-biofouling agent to prevent 
Streptococcus mutans from forming biofilms in the oral cavity by keeping them in 
planktonic state [74]. In line with these data, Caldara et al [186] showed that purified 
porcine gastric mucins, dominated by Muc5ac, prevent Pseudomonas aeruginosa 
from aggregating, thereby keeping them in a planktonic state where they are more 
susceptible to antibiotics. Campylobacteria jejuni was detected in the systemic 
organs of Muc1-/- mice following an oral challenge, but not in the systemic organs of 
Muc1+/+ mice [187]. Purified salivary MUC5B inhibited Influenza A virus in an in vitro 
assay [188].  
 
Following infection with respiratory syncytial virus (RSV), chemokine receptor 
CXCR2 triggered an increased mucus production dominated by Muc5ac in the 
airways of wild type mice compared to the CXCR2-/- mice, presumably to enhance 
the barrier function against infection [189]. Meanwhile, in the gastric mucosa 
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Helicobacter pylori infection impaired the mucin production and turnover in the mice 
stomach, thereby paralysing mucus clearance and promoting further infection [190]. 
The N-terminus of MUC7 showed anti-fungal and antibacterial activities in in vitro 
assays [142-144]. The purified MUC1 isolated from the breast milk of lactating 
mothers inhibited poxvirus in an in vitro assay [191]. Collectively, these studies 
highlight the antimicrobial properties of the mucins in general. 
 
Bergey et al [26] fractionated the human salivary samples using size exclusion 
chromatography and found that the mucin-rich fractions had anti-HV-1 activity. 
Accordingly, size exclusion chromatography-purified salivary mucins (MUC5B and 
MUC7) inhibited HIV-1 infection in in vitro assays [29, 192, 193], and so did the 
purified breast milk mucins from the breastfeeding mothers [194, 195]. Carias et al 
[31] reported a 2.5-fold increase of HIV penetration into the endo-cervical columnar 
epithelium, following a neuraminidase-mediated degradation of the cervical mucus 
layer from the human endo-cervical tissue explants. Habte et al [35] found that the 
purified cervical mucins inhibit HIV-1 in in vitro assays, while the crude cervical 
mucus plugs did not, despite a repertoire of antimicrobial factors present in these 
secretions [121]. Taken together, these studies show that the mucins in general and 
cervical mucins in particular exhibit anti-HIV-1 activity.   
 
Literature is accumulating on the anti-viral activities of the cervico-vaginal secretions 
coating the vaginal canal, while largely excluding the endo-cervical mucus, which 
seems to provide better protection in the ex vivo experiments [31]. Several studies in 
the field rarely address the pressing issue of HIV infection in the context of cell-
associated HIV-1 viruses, the most efficient physiological mode of HIV transmission 
[196, 197]. We aimed to characterize and define the anti-HIV-1 activity of the crude 
cervical mucus plugs and purified cervical mucins collected from HIV negative and 
HIV positive women in the contexts of cell-free and cell-associated HIV viruses.  
 
Our approach involved probing the individual samples against a panel of replication-
competent strains of HIV-1 in the context of cell-free viruses, allowing an unbiased 
analysis of individual variations between the individual donors. Assessing the anti -
HIV-1 activity of the crude cervical mucus plug in the context of cell-free viruses 
using two independent readouts allowed us to show the consistency of their anti -
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HIV-1 activity. We conducted infection assays in the context of cell-associated virus 
to investigate whether HIV-1 could overcome the barrier functions imposed by the 
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We aimed to characterize and define the barrier functions of the crude cervical 
mucus plugs and their cluster of purified mucins (samples) against a panel of 





 Investigate the anti-HIV-1 activity of the crude cervical mucus plugs and 
purified mucins against a panel of replication-competent strains of HIV-1 in 
the context cell-free virus using luciferase and flow cytometry-based GFP 
readouts. 
 Pin-point the mechanism of action behind the anti-HIV-1 activities of the study 
samples using time-of-addition and -lactamase-based assays. 
 Investigate the anti-HIV-1 activity of the crude cervical mucus plugs and 
purified mucins against HIV-1 in the context of cell-associated virus using a 
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Chapter – 3: Materials and Methods 
 
3.1. Materials 
Guanidine hydrochloride, ethylenediaminetetraacetic acid, N-ethylmaleimide, 
phenylmethanesulfonyl fluoride, caesium chloride, Sepharose CL-2B beads, periodic 
acid, pararosaniline hydrochloride, ammonium persulfate, glycerol, bromophenol 
blue, tetramethylethylenediamnie, dialysis tubing, acetic acid, sodium metabisulphite, 
hydrochloric acid, β-mercaptoethnaol, Tris, sodium chloride, sodium azide, N,N′-
methylenebisacrylamide, alkaline phosphatase-conjugated goat anti-rabbit polyclonal 
antibody and NBT/BCIP Detection Kit were purchased from Sigma-Aldrich, South 
Africa. Bradford assay reagent was purchased from Bio-Rad, South Africa and 
Vacutec AquaStain from Vacutec, South Africa. Nitrocellulose membrane was 
purchased from Amersham Biosciences, South Africa. Rabbit polyclonal anti -
MUC5AC and anti-MUC5B antibodies were a gift from Thornton’s Lab, University of 
Manchester, United Kingdom. Sucrose, RPMI 1640, Dulbbeco’s Modified Eagle’s 
Medium, Phosphate Buffered Saline were purchased from Sigma-Aldrich, Germany. 
Luciferase Assays System and CellTiter-Glo Luminescent Cell Viability Assay Kit 
were purchased from Promega, Germany. CalPhos Mammalian Transfection Kit was 
purchased from Takara Bio Europe, Germany. CCF4 staining kit was purchased 
from Invitrogen, Germany. Penicillin, streptomycin, L-glutamine, trypsin and CO2 
independent medium were purchased from Gibco, Germany. TZMbl cells, parental 
Jurkat cells, T20, efavirenz and maraviroc were obtained from NIH AIDS Reagent 
Programme, USA. PFA was purchased from Carl Roth, Germany. The cell culture 
flasks were purchased from Sardstedt and the cell culture plates from Geriner Bio 
One, Germany. HEK293T and PM1 cells were obtained from ATCC, USA. 
3.2. Ethics statement 
 
The study was approved by the Human Research Ethics Committee of the University 
of Cape Town (HREC REF: 102/2013) and the provincial health department of the 
Eastern Cape (EC_2016RP7_393). The samples were collected according to the 
principles expressed in the Declaration of Helsinki.    
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3.3. Study population and sample collection 
 
A group of 52 pregnant women of African black ethnicity, with a mean age of 25.5 
years, were recruited from the maternity unit of Mthatha General Hospital (MGH) in 
the Eastern Cape province between October 2016 and April 2017. Of these 52 
women, 28 (53.8%) were HIV negative while 24 (46.2%) were HIV positive. There 
were no inclusion or exclusion criteria set out during the recruitment process and the 
donation of samples was voluntary. The cervical mucus plugs of women in labour 
were either shed spontaneously or retrieved by a midwife during the routine cervical 
examinations and collected in 6 M guanidine hydrochloride (GuHCl) with protease 
inhibitors (10 mM EDTA, 5 mM NEM and 1 mM PMSF) [198]. The samples were 
kept at 4C until the end of the sample collection process, after which they were 
shipped to us at -80C.   
 
3.4. Preparation of the crude cervical mucus plugs 
 
Of the 52 samples, 16 (half from each cohort) were selected for preparation of the 
crude cervical mucus plugs based on the cervical mucus plug quantity (≥ 5 g), and 
throughout this study, the samples were analysed individually. The crude cervical 
mucus plugs were stirred slowly overnight at 4C. The solubilised material was 
centrifuged at 6000 rpm for 10 minutes at 4C to remove cell debris. The soluble 
supernatant was dialyzed against three changes of distilled water and freeze-dried at 
-50C/0.021 mBa using a Freeze Dryer (Labconco, USA) [35].   
 
3.5. Preparation of the purified cervical mucins 
 
Purification of the mucins from another batch of 16 samples (half from each cohort) 
was performed by caesium chloride density gradient ultracentrifugation and 
Sepharose CL-2B gel-filtration [198]. The samples were adjusted to a density of 1.4 
g/ml using caesium chloride (CsCl) and 4 M GuHCl. Ultracentrifugation was carried 
out in a 70Ti rotor using a Beckman ultracentrifuge (Beckman Coulter, South Africa) 
at 40000 rpm for 48 hours at 4C. After centrifugation, each sample was divided into 
nine 1 cm fractions. These fractions were weighed for the determination of density, 
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after which they were assayed for glycoproteins and proteins using periodic acid 
Schiff (PAS) and Bradford assays respectively. The absorbance values readings 
were measured at 585 nm [199] using an Anthos HT3 plate reader (Anthos Labtec 
Instruments, USA) and graphs generated by Microsoft Excel (Microsoft, 2016). 
 
The glycoprotein positive fractions, which fractionated at a density of 1.39 to 1.42 
g/ml, were pooled and subjected to Sepharose CL-2B gel-filtration on a 100 ml 
column (100 x 2 cm) and eluted with 0.2 M NaCl and 0.02% sodium azide at a flow 
rate of 1 ml/minute using a Miniplus 3 peristaltic pump (Gilson, South Africa). About 
110 fractions of 2 ml each were collected from each sample with FC 204 fraction 
collector (Gilson, South Africa), assayed for glycoprotein and protein contents using 
PAS and Bradford assays respectively, as mentioned above. The graphs were 
generated by Microsoft Excel (Microsoft, 2016). The glycoprotein-rich fractions that 
eluted in the exclusion volume (V0) were pooled and dialysed against three changes 
of distilled water at 1:30 ratio, frozen at -80C for 2 hours and freeze-dried at -
50C/0.021 mBa using a Freeze Dryer (Labconco, USA) [198]. 
          
3.6. Sodium dodecyl sulphate polyacrylamide-gel electrophoresis    
 
The crude cervical mucus plugs and purified mucins were characterized by 4-20% 
gradient sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE). 
The freeze-dried samples were reconstituted in 1% of SDS loading buffer (62 mM 
Tris-HCl, pH 6.8; 2.5% SDS; 10% glycerol; 0.01% bromophenol blue and 1% β-
mercaptoethanol) to a final concentration of 100 g/ml and resolved on 4-20% of 
SDS-PAGE at 120 V, 300 mA for 1 hour using the Laemmli method [200]. To 
visualize proteins, the gels were washed with distilled water for 10 minutes and 
incubated with Vacutec Aqua stain for 1 hour. To visualize sugars, the gels were 
washed with distilled water for 1 hour and fixed with 50% ethanol for 30 minutes. 
After 10-minute wash with distilled water, sugars in the gel were oxidized with 50% 
periodic acid for 30 minutes and reduced with 0.1% sodium metabisulphite in 10 mM 
HCl for 20 minutes. The pink colour was developed by incubating the gels with a 
decolourized Schiff reagent for 1 hour [201]. The gels were covered with 3M flip-
frame transparency protector (216 x 279 mm) and digitized using canon scanner 
(Canon, South Africa) to generate the TIF images.    
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3.7. Western blot analysis of the crude cervical mucus plug and 
purified mucins 
 
To identify the major gel-forming mucins in the cervix by the Western blots, the 
samples were prepared and resolved on 4-20% SDS-PAGE gels as mentioned 
above [200]. Following resolution, the samples were blotted onto nitrocellulose 
membranes at 4 V, 64 mA for 2 hours using electro-blot SV20-SDB (Sigma-Aldrich, 
UK). The membranes were rinsed with distilled water and blocked with 5% skimmed 
milk in PBS at 4C overnight. The membranes were then washed three times with 
PBST and probed with polyclonal antibodies (1:5 000) to MUC5AC (MAN-5ACl) and 
MUC5B (MAN-5Bl) in 5% skimmed milk for 1 hour at room temperature [35]. The 
unbound primary antibodies were washed three times with PBST, after which the 
membranes were probed with alkaline phosphatase-conjugated secondary antibody 
(1:10 000) in 5% skimmed milk. The unbound secondary antibody was washed off 
three times with PBST, after which the blots were developed using nitro blue 
tetrazolium chloride-5-bromo-4-chloro-3-indonyl phosphate (NBT/BCIP) as a 
substrate. The membranes were covered with 3M flip-frame transparency protector 
(216 x 279 mm) and digitized using canon scanner (Canon, South Africa) to 
generate the TIF images. 
 
3.8. CellTiter-Glo luminescent viability assays 
 
The CellTiter-Glo Luminescent Cell Viability Assay Kit, which quantifies the ATP 
molecules released by the metabolically active cells as a sign of viability, was used 
to assess the effect of the crude cervical mucus plugs and purified cervical mucins 
(samples) on the viability of TZMbl cells, clones of HeLa cells that have been 
engineered to overexpress CD4, CCR5 and luciferase [202]. The individual samples 
from the HIV negative and HIV positive groups were reconstituted in 10% Dulbbeco’s 
Modified Eagle’s Medium (DMEM), supplemented with penicillin-streptomycin (100 
units/ml-100 g/ml) and 2 mM L-glutamine, to a final concentration of 1 mg/ml. 
TZMbl cells were seeded overnight at 1x105 cells/well in 96-well plates and 
incubated in triplicates with 1 mg/ml of the individual samples. Ten percent of SDS in 
1 M HCl was used as a positive control for induction of cytotoxicity. The cells were 
incubated at 37C/5% CO2 for 48 hours. Post-incubation, the CellTiter-Glo substrate 
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was added directly into the cultures at 1:2 ratio and mixed for 2 minutes, followed by 
a 10-minute incubation in the dark to stabilize the luminescent signals. The samples 
(100 l) were then transferred into 96-well luminometer plates in which the relative 
light units (RLUs) were measured using luminometer (Sirius, Berthold Detection 
Systems). The RLUs were background (media only control) subtracted and 
normalized to the negative control wells (untreated cells). 
       
3.9. Production of the virus stocks and titration  
 
HEK293T cells, which express SV40 T-antigen, were seeded in 10% DMEM at 
2x106 cells/10 cm cell culture dish overnight at 37C/5% CO2 and transfected with 60 
g of pro-viral plasmid DNA encoding full length SIV and HIV-1 strains. To produce 
HIV-1 strains carrying -lactamase-Vpr, HEK293T cells were transfected with three 
DNA plasmids per 10 cm cell culture dish: pYU-2/pNL4.3 (60 g), pBlaM-Vpr (20 g) 
and pAdvantage (8 g) [203, 204]. All the transfections were carried out using the 
CalPhos Mammalian Transfection Kit. Following a change of medium after 4-hour 
incubation, the cultures were incubated at 37C/5% CO2 for 48-72 hours. Post 
transfection, the cell-free virus particles were harvested from the supernatants, 
filtered through 0.45 m filters (Millipore, Germany) and concentrated using 20% 
sucrose cushion method (30000 rpm, 4C, 1.5 hours) [202]. The concentrated 
viruses were titrated on TZMbl cells using -galactosidase-based blue cell assay 
[202]. The primary isolate of HIV-1BaL was obtained from the NIH AIDS Reagent 
Programme (USA) and passaged in PM1 cells cultured in 10% Roswell Park 
Memorial Institute (RPMI) 1640 medium [205]. 
 
3.10. TZMbl cell-based luciferase assays 
  
TZMbl cells in 10% DMEM were seeded at 1x105 cells/well in 96-well plates and 
incubated at 37C/5% CO2 overnight. The viruses were incubated with two-fold 
serially diluted samples for 1 hour at 37C/5% CO2, before infecting TZMbl cells for 
48 hours at 37C/5% CO2. Post-infection, the supernatant was aspirated, after which 
the cells were lysed with 1% Cell Culture Lysis Buffer for 10 minutes at room 
temperature. Ten microliters of the cell lysate were transferred into 96-well 
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luminometer plates and mixed with 30 l of Luciferase Assay Substrate. The RLUs 
were measured using luminometer (Sirius, Berthold Detection Systems). The 
background was subtracted using the untreated wells, divided by the RLUs from the 
virus control wells and multiplied by 100 to generate percentage infection: % 
infection = [average RLU (treated)—average RLU (CC)/average (VC)—average RLU 
(CC)] [206]. The data were analysed using GraphPad Prism v5 (La Jolla, CA, USA). 
 
3.11. Heat inactivation assays 
 
To investigate the pro-SIVmac239 activity of sample 47, which was absent in other 
samples, an aliquot (1 mg/ml) was heated at 96C for 20 minutes at 600 rpm using 
Eppendorf Thermomixer (Eppendorf, Germany) and cooled down for 10 minutes at 
4C. SIVmac239 was incubated with the heated and unheated aliquots of sample 47 for 
1 hour at 37C/5% CO2. In 96-well plates, TZMbl cells (1x105 cells/well) were 
infected in triplicates with the mucus-virus mixtures for 48 hours at 37C/5% CO2. 
Post-infection, the luciferase assays were conducted to quantify luciferase 
expression in TZMbl cells as mentioned above. The data were analysed using 
GraphPad Prism v5 (La Jolla, CA, USA).  
 
3.12. Time-of-addition assays 
 
In 10% DMEM, TZMbl cells were seeded in 96-well plates overnight at 1x105 
cells/well prior to infection with HIV-1NL4.3. These assays were conducted under three 
independent conditions to characterize the mode of action by which the crude 
cervical mucus plugs potently inhibit HIV-1. Firstly, TZMbl cells were incubated with 
cervical mucus plugs for 1 hour at 37C/5% CO2, prior to infection with HIV-1NL4.3 for 
48 hours. Secondly, TZMbl cells were infected with HIV-1NL4.3 for 1 hour at 37C/5% 
CO2 and incubated with cervical mucus plugs for 48 hours. Thirdly, HIV-1NL4.3 was 
incubated with cervical mucus plugs for 1 hour at 37C/5% CO2 prior to infection of 
TZMbl cells for 48 hours. Following 48-hour incubations at 37C/5% CO2, the 
luciferase assays were conducted to quantify the luciferase expression in TZMbl 
cells as mentioned above. The data were analysed using GraphPad Prism v5 (La 
Jolla, CA, USA).  
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3.13. The -lactamase-based HIV-1 fusion assay 
 
TZMbl cells in 10% DMEM were seeded at 2x105/well in 12-well plates overnight at 
37C/5% CO2. On the next day, the BlaM-Vpr HIV-1 strains were incubated with 
samples (1 mg/ml) for 1 hour at 37C/5% CO2. As the positive controls for inhibition 
of infection, the cells were either incubated with 25 M maraviroc (HIV-1YU-2 BlaM-
Vpr) or 50 M T20 (HIV-1NL4.3 BlaM-Vpr) for 1 hour prior to infection. The cells were 
infected with the virus-sample mixture for 4 hours at 37C/5% CO2, after which the 
infections were stopped. Post-infection, the cells were washed with 10% CO2 
independent medium and then phosphate buffered saline (PBS) before trypsinization 
for 4 minutes at 37C/5% CO2. The cells were then re-suspended in 10% CO2 
independent medium and centrifuged (5000 rpm, 5 minutes, 4C). The cell pellets 
were washed, re-suspended in 10% CO2 independent medium, centrifuged (5000 
rpm, 5 minutes, 4C) and stained with CCF4 overnight at room temperature. The 
stained cells were washed with PBS, centrifuged (5000 rpm, 5 minutes, 4C) and 
fixed with 4% PFA for 90 minutes at room temperature. The cells were given a final 
PBS wash, centrifuged (5000 rpm, 5 minutes, 4C) and re-suspended in PBS. The 
CCF4 spectral shift was analysed by acquiring 20 000 events in FITC-A and Horizon 
V450-A channels using a multi-parameter LSR ll flow cytometry (BD Biosciences). 
The data were analysed by FlowJo v10 (Tree Star, Ashland, USA) and GraphPad 
Prism v5 (La Jolla, CA, USA).         
 
3.14. Cell-to-cell infection assays 
 
As the donor cells, HEK293T cells in 10% DMEM were seeded overnight at 2x105 
cells/well in 24-well plates and transfected with 2 g of pro-viral DNA plasmid 
encoding full length HIV-1NL4.3-GFP using the CalPhos Mammalian Transfection Kit. 
After 4 hours of incubation, the medium was changed followed by incubation of 
cultures for 24 hours at 37C/5% CO2. The virus-producing HEK293T cells were 
incubated (1:2 ratio) with 1 mg/ml of crude cervical mucus plug for 1 hour at 
37C/5% CO2 and co-cultured with parental Jurkat T-cells (1x106 cells/well), which 
are the immortalized CD4+ human T-lymphocytes that are sensitive to HIV-1 
infection, for 24 hours at 37C/5% CO2 in the presence or absence of efavirenz. 
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Parental Jurkat T-cells were maintained in 10% RPMI 1640 medium supplemented 
with Pen-Strep and L-glutamine prior to co-culture experiments. As the negative and 
positive controls, parental Jurkat T-cells were co-cultured with HEK293T cells in the 
absence or presence of efavirenz respectively. Post-infection, the cells were 
harvested, PBS-washed and fixed with 4% PFA for 90 minutes at room temperature. 
The GPF signal from parental Jurkat T-cells was measured by acquiring 50 000 
events in FL1-H and FL4-H channels using FACS-Calibur flow cytometry (BD 
Bioscience), The data were analysed using FlowJo v10 (Tree Star, Ashland, USA) 
by gating on the live population of parental Jurkat T-cells to exclude HEK293T cells 
and other cell debris. Statistical analysis was performed using GraphPad Prism v5 
(La Jolla, CA, USA).         
 
3.15. Jurkat T-cell-based infection assays in the context of cell-free 
virus 
 
Cell-free HIV-1NL4.3-GFP was incubated with 1 mg/ml of cervical mucus plugs at 1:2 
ratio for 1 hour at 37C/5% CO2, prior to 48-hour infection of parental Jurkat T-cells 
at 1x106 cells/well in 12-well plates. As the positive control for inhibition of infection, 
parental Jurkat T-cells were incubated with 25 M efavirenz for 1 hour at 37C/5% 
CO2 prior to infection with HIV-1NL4.3-GFP for 48 hours. Post-infection, the cells were 
harvested, washed with PBS, centrifuged (5000 rpm, 5 minutes, 4C) and fixed with 
4% PFA for 90 minutes at room temperature. The GFP signal was measured by 
acquiring 50 000 events in FL1-H and FL4-H channels using FACS-Calibur flow 
cytometry (BD Bioscience). The data were analysed using FlowJo v10 (Tree Star, 
Ashland, USA) and GraphPad Prism v5 (La Jolla, CA, USA). 
 
3.16. Statistical analysis 
 
One-way ANOVA (nonparametric) coupled to Dunnett’s multiple comparison test 
was used to compare the means. The descriptive statistics is represented by the 
mean and standard error of the mean (SEM), where P≤0.05 was considered 
significant. The statistical tests were conducted using GraphPad Prism v5 (La Jolla, 
CA, USA). 
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Chapter – 4: Results 
 
4.1. Clinical profile of the study cohort 
 
This study comprised 52 women of African black ethnicity with a mean age of 25.5 
years, 28 (53.8%) of whom were HIV negative and 24 (46.2%) were HIV positive. 
There are no clinical data for 16 of the purified cervical mucin samples, eight from 
each cohort of HIV negative and HIV positive women. For the crude cervical mucus 
samples, one of the HIV negative women presented with an E. coli positive urinary 
tract infection, which was consecutively treated with a cocktail of antibiotics: 500 mg 
amoxicillin, 375 mg augmentin, 960 mg co-trimoxazole and 2 g metronidazole. The 
rest of the HIV negative women presented with no symptoms of genitourinary tract 
infection during hospitalization. One HIV positive woman presented with minor 
genital warts for which she was not treated prior to sample collection. Another one 
presented with an offensive vaginal discharge for which she was treated with 500 mg 
amoxicillin, 1 g ampicillin, 400 mg metronidazole and one nystatin vaginal pessary. 
The CD4 count ranged between 270-727 cells/mm3 (mean 413 cells/mm3) for the 
HIV positive cohort, whose members were all on HAART treatment, with a duration 
range of 1 to 36 months. The viral load ranged from being undetectable to 4980 RNA 
copies/ml.      
 
4.2. Biochemical purification of the cervical mucins 
 
Mucin purification and isolation from individual samples was performed by a single 
density gradient ultracentrifugation step in CsCl, followed by gel-filtration on a 
Sepharose CL-2B column to enrich the population of large polymeric mucins eluting 
in the excluded volume (V0) of the column, and separate from the degraded subunits 
and any low molecular weight protein contaminants eluting in the included volume 
(Vi) [198]. In agreement with Carlstedt et al [198], the cervical mucins fractionated at 
an average density of 1.4 g/ml, high in PAS positive material and low in protein 
content (Fig. 1A-1B). The glycoprotein-rich fractions (fractions 3-6) were pooled from 
individual samples for subsequent assays. The purification graphs show that there 
were no biochemical differences between the HIV negative and HIV positive cohorts.  
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The gel-filtration graphs showed a clear separation of V0 and Vi for PAS positive 
material and the protein content for both cohorts (Fig. 1C & 1D). The high molecular 
weight mucin polymers eluted in the V0 fractions while the low molecular weight 
proteins and glycoproteins eluted in the V i fractions (Fig. 1C & Fig. 1D) [201]. The 
glycoprotein-rich V0 fractions were pooled, dialyzed against three changes of distilled 
water and freeze-dried. The samples from both cohorts showed comparable 
glycoprotein and protein content, which eluted at about the same fractions, thereby 
suggesting similar biochemical characteristics of mucins from the HIV negative and 
HIV positive cohorts. 





Figure 1: Biochemical preparation of the cervical mucins. Mucins were purified 
from individual cervical mucus plugs that were collected from the HIV negative and 
HIV positive cohorts by caesium chloride density gradient ultracentrifugation (A & B). 
Purified cervical mucins from the HIV negative (A) and HIV positive (B) cohorts were 
further subjected to Sepharose CL-2B gel-filtration (cut-off 70x104 kDa) (C & D) and 
assayed by PAS and Bradford assays for glycoproteins and proteins respectively. 
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4.3. Sodium dodecyl polyacrylamide-gel electrophoresis  
 
The crude cervical mucus plugs and purified cervical mucins were resolved on 4-
20% gradient SDS-PAGE gels in parallel and the gels were stained for glycoproteins 
and proteins with PAS and Vacutec AquaStain respectively, to assess the degree of 
purity of mucins following gel-filtrations. Following protein staining (Fig. 2A & 2C), the 
crude cervical mucus plugs showed a spectrum of proteins with different 
electrophoretic mobilities spanning the entire length of the gels. The protein staining 
intensified with decreasing molecular weight (Fig. 2A & 2C), suggesting a high 
presence of fast-migrating species. Some low intense material was seen stuck in the 
spacer gel, suggesting the presence of high molecular weight species, likely 
glycoproteins with inaccessible protein backbones, hence the poor protein staining 
(Fig. 2A & 2C). The individual samples exhibited different intensities, with 130 kDa 
band among certain samples (Fig. 2A; samples 1, 2, 4, 18 & 32; Fig. 2C; samples 
12, 28 & 48) regardless of the donor’s HIV status. There was also a 250 kDa band 
exclusively present among certain samples from the HIV positive cohort (Fig. 2C; 
samples 7, 12, 14 & 28). The PAS stain (Fig. 2B & 2D) was clearly of large size, with 
material in the spacer gel, at the beginning of the running gel and even entering the 
running gel, suggesting presence of slowly migrating and heavily glycosylated 
species, a typical electrophoretic pattern of the mucins in SDS-PAGE [198, 201, 
207]. The intensities of the 250 and 130 kDa bands decreased following PAS stain 
(Fig. 2B; samples 1, 2, 4, 18 & 32; Fig. 2D; samples 12, 28 & 48), suggesting a 
lesser degree of glycosylation. These two bands correspond with a molecular weight 
range of intact IgA and IgG [208], the dominating immunoglobulins in the cervical 
mucus plugs [155]. Several protein bands of lower molecular weight were lost in 
several samples following PAS staining, while certain samples retained some PAS 
positive bands of 55 kDa (Fig. 2B; samples 1, 2, 4, 18 & 39; Fig. 2D; samples 12, 
14 & 28), corresponding to the molecular weights of heavy chains of IgA and IgG 
[155, 208], and α-1 acid glycoprotein [209]. 
 
Compared to the crude cervical mucus plugs, protein staining of the purified cervical 
mucins in the V0 fractions showed an effective removal of the low molecular weight 
species and retention of the high molecular weight species (Fig. 2E; samples 8, 10, 
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11 & 24; Fig. 2G; samples 30, 40, 43 & 44). There were low molecular species in the 
Vi fractions as expected, dominated by a 55 kDa band (Fig. 2E; samples 8, 10 & 
11; Fig. 2G; samples 30, 40, 43 & 44), suggesting protein separation based on the 
molecular weights as reflected in the gel-filtration profiles (Fig. 1C & 1D). This 55 
kDa band in the Vi fractions was independent of the donor’s HIV status and could be 
a heavy chain of an immunoglobulin [155, 208] or α-1 acid glycoprotein [209]. PAS 
staining (Fig. 2F & 2H) confirmed that the slowly migrating species on top of the gels 
are heavily glycosylated species of higher molecular weight. Also, the intensity of 
55 kDa band in the V0 fractions decreased following PAS (Fig. 2F; samples 8, 10 & 
11; Fig. 2H; samples 30, 40, 43 & 44), suggesting a lesser degree of glycosylation.  






Figure 2: Characterization of the crude cervical mucus plugs and purified 
cervical mucins by SDS-PAGE. The individual crude cervical mucus plugs from the 
study cohorts were prepared by slow stirring overnight at 4C and centrifuged at 600 
rpm for 10 minutes at 4ºC to remove cell debris. The supernatants were dialyzed 
against distilled water (ratio1:30) and freeze-dried. The freeze-dried crude cervical 
mucus samples (A-D) from the HIV negative (A-B) and HIV positive (C-D) cohorts 
were reconstituted in 1% SDS loading buffer and resolved on 4-20% gradient gels. 
The gels were stained with Vacutec AquaStain and PAS for proteins and 
glycoproteins respectively. The purified cervical mucins (E-H) from HIV negative (E-
F) and HIV positive (G-H) cohorts were characterized on 4-20% gradient SDS-PAGE 
as mentioned above. For each sample, the V0 and Vi were analysed in parallel.  
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4.4. Western blot identification of the gel-forming cervical mucins 
 
MUC5AC and MUC5B, the predominant gel-forming mucins in the endo-cervix [96] 
were identified using Western blots. The crude cervical mucus plugs from the HIV 
negative cohort showed a positive signal for both MUC5AC (Fig. 3A; samples 1, 2, 4, 
5, 18, 25, 32 & 39) and MUC5B (Fig. 3A; samples 2, 4, 5, 18, 25, 32 & 39), with 
varying intensities between individual samples. However, sample 1 was negative for 
MUC5B (Fig. 3B). The samples from the HIV positive cohort were also positive for 
MUC5AC (Fig. 3C; samples 7, 12, 14, 22, 28, 42 & 48) and MUC5B (Fig. 3D; 
samples 7, 12, 14, 22, 28, & 48), with samples 42 and 47 showing trace amounts of 
MUC5B. Generally, the gels show a high intensity of bands from the HIV positive 
cohort (Fig. 3C & 3D). Purified cervical mucins generally showed cleaner and intense 
bands for the respective mucins (Fig. 3E-3H) compared to the crude cervical mucus 
plugs (Fig. 3A-3D). This suggests an improved access of the antibodies to the mucin 
antigens due to effective removal of other hundreds of proteins found in the cervical 
mucus plugs as reported by the mass spectrometry studies [121, 174]. The samples 
from HIV negative cohort showed low signals for MUC5AC (Fig. 3E) compared to 
MUC5B (Fig. 3F). The intensity of MUC5AC (Fig. 3G) signal was high in the HIV 
positive cohort, while that of MUC5B also increased among certain samples (Fig. 3H; 
samples 9, 15, 30 & 43). In the context of MUC5AC, these data confirm a recognized 







Figure 3: Identification of the major gel-forming cervical mucins. The freeze-
dried crude cervical mucus plug (A-D) and purified cervical mucins (E-H) samples 
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from the HIV negative and HIV positive cohorts were reconstituted in 1% SDS 
loading buffer and resolved on 4-20% SDS-PAGE. The proteins were blotted onto 
nitrocellulose membranes, which were probed with anti-MUC5AC and anti-MUC5B 
rabbit polyclonal antibodies, washed and re-probed with goat anti-rabbit monoclonal 
secondary antibody. The protein bands were developed using NBT/BCIP substrate. 
 
4.5. Cell viability assays 
 
The CellTiter-Glo Luminescent Cell Viability Assay was used to investigate the 
extent to which TZMbl cells tolerate treatment with the crude cervical mucus plugs 
and purified cervical mucins (samples). This assay quantifies the ATP molecules 
generated by the metabolically active cells as a measure of cell viability. The 
samples were reconstituted in 10% DMEM to a final concentration of 1 mg/ml. TZMbl 
cells were incubated with the samples for 48 hours at 37C/5% CO2, followed by 
quantification of the generated ATP molecules in the form of relative light units 
(RLUs) using luminometer (Sirius, Berthold Detection System), which were 
normalized to the negative control. Following incubation with the crude cervical 
mucus plug and purified cervical mucins (Fig. 4A-D), TZMbl cells showed an average 
99% of cell viability compared to those incubated with 10% SDS in 1 M HCl (positive 
control), which showed significantly decreased cell viability. There were no well-
defined differences on the cell viabilities between the crude cervical mucus plugs 
and purified cervical mucins nor were there any HIV status-based differences. These 
data show that TZMbl cells can equally tolerate the crude cervical mucus plugs and 
purified cervical mucins regardless of the donor’s HIV status, while reflecting the 
efficiency of dialysis in removing high salt content used during the biochemical 
preparation of the study samples.   
 
 
                                                                                                                
 




Figure 4: Effect of the crude cervical mucus and purified cervical mucins on 
the viability of TZMbl cells. The freeze-dried crude cervical mucus plugs (A-B) and 
purified cervical mucins (C-D) from the HIV negative and HIV positive cohorts were 
reconstituted in 10% DMEM to a final concentration of 1 mg/ml. The individual 
samples were used to inoculate TZMbl cells in triplicates for 48 hours, after which 
the ATP molecules were quantified from the cell lysates using a CellTiter-Glo 
Luminescent Cell Viability Kit. The data were analysed by GraphPad Prism v5 using 
One-way ANOVA (nonparametric) to compare the means. Error bars represent the 
mean  SEM of the triplicates from one experiment.   
 
4.6. Anti-HIV-1 activity of the crude cervical mucus plugs in the 
context of cell-free virus: Firefly luciferase-based reporter assay 
 
The aim was to extend the findings of Habte et al [35] in our laboratory, who reported 
that the crude cervical mucus plugs from the HIV negative women do not inhibit HIV-
1 in the in vitro assays, despite comprising a spectrum of immunological factors 
[121], some of which are absent in the cervical mucus of non-pregnant women [173]. 
This study further had crude cervical mucus plugs from the HIV positive cohort, while 
Habte et al [35] only used samples from the HIV negative cohort. We hoped to detect 
the difference, if any, between samples from the HIV negative and HIV positive 
cohorts. Unlike Habte et al [35], the samples were probed individually against a 
panel of HIV-1 (plus SIVmac239) replication-competent strains from different subtypes 
and tropisms to learn more about their anti-viral coverage from different aspects. 
Infection efficiency was analysed in TZMbl cells using luciferase assays that quantify 
infection on the basis of increasing or decreasing signals in HIV’s Tat-driven fire fly 
luciferase reporter gene expression following infection. 
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TZMbl cells were incubated with 2-fold serially diluted samples for 1 hour at 37C/5% 
CO2, followed by 48-hour infection under similar conditions, after which the infections 
were analysed using luciferase assays. Unlike Habte et al [35] who showed that the 
crude cervical mucus plugs do not inhibit HIV-1 in an in vitro assay, the cervical 
mucus plugs generally inhibited several strains of HIV-1, irrespective of the donor’s 
HIV status. The samples from different donors exerted a selective inhibition against 
HIV-1 infection, depending on the infecting strain. Most samples collected from the 
HIV positive cohort were more potent compared to most samples collected from the 
HIV negative cohort, probably due to the ability of cervical mucus plugs to retain HIV-
specific antibodies from the circulatory system [174] and HAART regimens [211]. 
However, sample 25 (Fig. 5F) from the HIV negative cohort was just as potent 
against several strains of HIV-1. This suggest that this potency is not exclusively 
mediated by HIV infection, but presumably by certain factors that may vary between 
individuals in terms of antimicrobial content of the cervical mucus plugs. 
 
From a panel of study viruses, HIV-1BaL proved to be the most refractory strain, and 
its refractoriness was more pronounced in the HIV negative cohort (Fig. 5A-5H), 
where several samples showed a slight enhancement of HIV-1BaL infection. Sample 
7 (Fig. 5I) from the HIV positive cohort exhibited a similar characteristic, suggesting 
that this refractoriness of HIV-1BaL is not exclusively mediated by HIV infection, but 
probably by the inter-individual variations on which HIV infection may impact. While 
certain samples showed slight enhancement of HIV-1BaL infection, sample 47 (Fig. 
5O) showed a potent inhibition compared to all the study samples. Surprisingly, the 
same sample 47 (Fig. 5O) drastically enhanced SIVmac239 infection, highlighting the 
heterogeneity between and within cervical secretions [36, 212]. 
 
Depending on the infecting HIV-1 strain, certain samples potently suppressed HIV-1 
infection, but that was hardly seen for SIVmac239, even from the most potent samples 
despite the donor’s HIV status. Except for sample 47, the inhibition profile of 
SIVmac239 consistently began with high sensitivity to the crude cervical mucus plugs 
and quickly gained resistance before the HIV-1 strains, after which further increase 
in cervical mucus plug concentration had little or no effect on it. SIVmac239, a rhesus 
macaque immunodeficiency-causing virus, was included to extend our investigation 
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to other non-HIV mucosal transmitted viruses. From a tropism point of view, the X4 
strains (HIV-1NL4.3 & HIV-1LAI) were more susceptible to inhibition by the crude 
cervical mucus plugs compared to the R5 strains of HIV-1 and SIV (HIV-1BaL, HIV-
1YU-2, HIV-1CH198 & SIVma239), coherent with a recognized predominant exclusion of 
the X4 viruses and selective transmission of the R5 viruses at the female genital 
mucosal surfaces during the initial stages of HIV infection [213, 214].       





Figure 5: Luciferase reporter assay-based analysis of the anti-viral activity of 
the crude cervical mucus plugs in the context of cell-free virus. Crude cervical 
mucus plugs from the HIV negative (A-H) and HIV positive (I-P) cohorts were probed 
against a panel of replication-competent strains of HIV-1 and SIVmac239 in the context 
of cell-free virus. The viruses were incubated with two-fold serially diluted individual 
crude cervical mucus plugs for 1 hour at 37C/5% CO2 in a humidified incubator prior 
to infection of TZMbl cells for 48 hours, after which luciferase expression was 
measured using Luciferase Assay System. The dose-response curves were 
generated by GraphPad Prism v5 using One-way ANOVA (nonparametric) analysis 
to compare the means. The error bars represent the mean  SEM of duplicates from 
three experiments. 
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4.7. Anti-HIV-1 activity of the purified cervical mucins in the context 
of cell-free virus: Firefly luciferase-based reporter assay 
 
The anti-HIV-1 activity of the purified cervical mucins from the HIV negative cohort 
has been reported [35], but not in comparison to that of the purified cervical mucins 
from the HIV positive cohort. Due to limited quantity of the purified cervical mucins, 
the samples were probed three times in duplicates against two HIV-1 strains that 
were less (HIV-1BaL) and more (HIV-1NL4.3) susceptible to inhibition by the crude 
cervical mucus plugs respectively (Fig. 5). The inhibition assays were conducted as 
mentioned above, after which the purified cervical mucins showed comparable anti -
HIV-1 activity regardless of the donor’s HIV status, suggesting that HIV infection 
does not appreciably change the anti-HIV-1 activity of the cervical mucins (Fig. 6). 
However, there was a noticeable evidence of the inter-individual variations [121]. 
 
Unlike the crude cervical mucus plugs, there was no well-defined selective inhibition 
against the infecting HIV-1 strains in the context of purified cervical mucins and the 
inhibition profiles were comparable. There was no enhancement of HIV-1 infection 
by the purified cervical mucins, suggesting that at least this enhancement is not 
exclusively mediated by the mucins. The purified cervical mucins did not show 
selective transmission of the R5 strains over X4 strains, suggesting that the mucins 
alone do not mediate this gatekeeping character, and if they do at all, they likely do 
so synergistically with other components of the cervical mucus plug. Interestingly, 
unlike the crude cervical mucus plugs from the HIV negative cohort that could barely 
inhibit HIV-1BaL (Fig. 5A-5H), the purified cervical mucins from the HIV negative 
cohort inhibited HIV-1BaL (Fig. 6A-6H). On the other hand, the crude cervical mucus 
plugs showed high potency against HIV-1NL4.3 (Fig. 5A-5H), while the purified mucins 
showed less potency (Fig. 6A-6H), suggesting that the mucins alone are not 
responsible for the varying potencies seen in the context of crude cervical mucus 
plugs. In overall, the purified cervical mucins were less potent compared to the crude 
cervical mucus plugs, most likely due to the elimination of non-mucin factors found in 
the cervical mucus plugs [121], which could probably synergize with mucins against 
HIV-1.      
                                                                                                                
 






Figure 6: Luciferase reporter assay-based analysis of the anti-viral activity of 
the purified cervical mucins in the context of cell-free virus. Purified cervical 
mucins from the HIV negative (A-H) and HIV positive (I-P) cohorts were probed 
against a panel of replication-competent strains of HIV-1 in the context of cell-free 
virus. The viruses were incubated with two-fold serially diluted purified cervical 
mucins for 1 hour at 37C/5% CO2 in a humidified incubator prior to infection of 
TZMbl cells for 48 hours, after which luciferase expression was measured using a 
Luciferase Assay System. The dose-response curves were generated by GraphPad 
Prism v5 using One-way ANOVA (nonparametric) analysis to compare the means. 
The error bars represent the mean  SEM of duplicates from three experiments.  
 
4.8. Enhancement of SIVmac239 infection by crude cervical mucus 
plug 
 
The pro-SIVmac239 activity of sample 47 was investigated under heated (96°C, 20 
minutes, 600 rpm) and unheated conditions. The aim was to heat-inactivate the 
potential infection-enhancing factors and reduce their activity if they are 
proteins/glycoproteins, since they are generally susceptible to heat inactivation. 
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SIVmac239 was incubated with heated (but cooled down) and unheated aliquots of 
sample 47 for 1 hour at 37C/5% CO2, before infecting TZMbl cells for 48 hours 
under similar conditions. Post-infection, the firefly luciferase assays were conducted 
to assess the level of infection. Interestingly, the enhancement of SIVmac239 infection 
was significantly reduced after heat inactivation of sample 47 compared to its 
unheated aliquot (Fig. 7B), suggesting that these pro-SIVmac239 factors are more 
likely to be proteins or glycoproteins. 
    
 
 
Figure 7: Pro-SIVmac239 activity of sample 47 from an HIV positive patient. After 
detecting an enhanced infectivity of SIVmac239 (A), sample 47 was probed against 
SIVmac239 under unheated (active) and heated (inactive) conditions before infecting 
TZMbl cells in triplicates for 48 hours. Post-infection, luciferase expression was 
measured from the cell lysates of TZMbl cells using Luciferase Assay System. The 
data from triplicates of one experiment were analysed by GraphPad Prism v5 (B) 
using One-way ANOVA (nonparametric). The error bars represent the mean  SEM.  
 
4.9. Characterizing the mode of action of the crude cervical mucus 
plug against HIV-1 
 
The mode of action that the cervical mucus plugs must employ in order to provide an 
efficient barrier against the invading pathogens was investigated under three 
conditions: incubation of TZMbl cells with cervical mucus plugs for 1 hour prior to 
HIV-1 infection, HIV-1 infection of TZMbl cells for 1 hour prior to incubation with 
cervical mucus plugs and incubation of HIV-1 with the cervical mucus plugs for 1 
hour prior to infection of TZMbl cells respectively (Fig. 8A). The cultures were 
incubated at 37C/5% CO2 for 48 hours, followed by the luciferase assays to 
measure the level of infection.  
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Compared to the virus only control, there was significant inhibition of HIV infection 
across all the conditions despite the donor’s HIV status (Fig. 8B-8E). The incubation 
of TZMbl cells with cervical mucus plugs prior to infection showed the least inhibition 
of HIV-1 infection across all samples. One-hour infection of TZMbl cells prior to 
incubation with cervical mucus plugs showed a second-best inhibition of HIV-1 
infection, which partly varied between samples since there was no such evidence in 
sample 4 (Fig. 8C). The incubation of HIV-1 with cervical mucus plugs prior to 
infection of TZMbl cells showed the most potent inhibition of HIV-1 when compared 
to other conditions. Together, these data point to the cervical mucus plug as more of 
a virus-directed inhibitor than a cell-directed inhibitor, thereby supporting its role in 
the selective transmission of HIV-1 strains seen in the luciferase assays (Fig. 5).  
        
 
 
Figure 8: Mode of action through which the crude cervical mucus plugs inhibit 
HIV-1 infection. Schematic illustration showing a sequence of events conducted 
during the time-of-addition assays (A). Mode of action by the crude cervical mucus 
plugs from the HIV negative (B-C) and HIV positive (D-E) cohorts was studied using 
replication-competent HIV-1NL4.3 under three conditions: one-hour TZMbl cells 
incubation with mucus prior to infection (infection after treatment), one-hour TZMbl 
cells infection with virus prior to incubation with mucus (infection before treatment) 
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and one-hour incubation of HIV-1NL4.3 with mucus prior to infection of TZMbl cells 
(virus pre-treatment) at 37C/5% CO2. Cell lysates from TZMbl cells were used to 
measure luciferase expression after 48 hours by Luciferase Assay System. The data 
were analysed by GraphPad Prism v5 using One-way ANOVA (nonparametric) and 
the error bars represent the mean  SEM of triplicates from one experiment.   
 
4.10. -lactamase-Vpr fusion assay in the context of HIV-1YU-2: 
Crude cervical mucus plugs 
 
The -lactamase-based fusion assay was performed to investigate the stage of HIV-
1 replication at which the cervical mucus plugs inhibit HIV-1 infection, with the aim of 
recapitulating the data from the luciferase assays (Fig. 5). This flow cytometry-based 
fusion assay measures a spectral shift in CCF4 due to the -lactamase (BlaM)-
mediated cleavage following HIV fusion with a target cell [203, 204]. HIV-1YU2 BlaM-
Vpr was incubated with cervical mucus plugs (1 mg/ml) for 1 hour at 37C/5% CO2 
before infecting TZMbl cells in triplicates for 4 hours under similar conditions. The 
cells were CCF4-stained overnight at room temperature, after which the CCF4 
spectral shift was analysed by acquiring 20 000 events using a multi-parameter LSR 
ll flow cytometry (BD Biosciences). The untreated cells, HIV-1YU-2 BlaM-Vpr and 
maraviroc-treated cells were used as controls, and the data were analysed using 
FlowJo v10 (Tree Star, Ashland, USA) and GraphPad Prism v5 (La Jolla, CA, USA). 
 
Using unstained mock TZMbl cells, a scatter plot (FSC-A/FSC-H) was generated, 
from which the live population of singlets was gated and a CCF4-stained mock used 
to set up a gate. The gate was applied to the test samples to determine the spectral 
shift of CCF4 as the results of -lactamase-mediated cleavage, which indicates 
successful membrane fusion between HIV and a target cell. The data (Fig. 9A) show 
that, irrespective of the donor’s HIV status, certain crude cervical mucus plugs inhibit 
membrane fusion between HIV-1 and the target cells. 
 
However, this may not be the only stage of HIV replication at which these cervical 
mucus samples inhibit HIV infection, since we have only looked at the fusion stage 
that typically comes after attachment—two essential events that HIV performs 
outside a target cell. Given the degree of heterogeneity between and within the 
samples, it could also be that some samples block viral attachment to the target cell 
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before fusion or even act at the post-entry stages. Accordingly, samples 4 (partially) 
and 22 (potently) inhibited HIV-1YU-2 infection in the luciferase assays (Fig. 5C & 5L), 
but quantification of the fusion assays (Fig. 9B) shows intact membrane fusion of 
HIV-1YU-2 with TZMbl cells in the presence of the very same samples. This suggests 
a possibility of acting at the post entry stages of HIV-1 replication, a mystery that 
awaits further investigation.  
   
 
 
Figure 9: Mechanism behind the anti-HIV-1 (HIV-1YU-2) activity of the crude 
cervical mucus plugs. Crude cervical mucus plugs from the study cohorts were 
probed in triplicates against HIV-1YU-2 BlaM-Vpr for 1 hour before infecting TZMbl 
cells for 4 hours. Post-infection, the cells were washed with 10% CO2 independent 
medium and PBS, after which they were trypsinized and re-suspended in 10% CO2 
independent medium. Re-suspended cells were pelleted, PBS-washed and stained 
with CCF4 overnight at room temperature. The CCF4 stained cells were PBS-
washed and fixed with 4% PFA prior to analysis of a -lactamase-mediated CCF4 
cleavage using a multi-parameter LSR ll flow cytometry (BD Biosciences). FACS dot 
plots show the degree of CCF4 cleavage in untreated and treated cells as a 
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reflection of HIV-1 fusion with the target cells (A). CCF4 cleavage was quantified by 
GraphPad Prism v5 using One-way ANOVA analysis (nonparametric) (B). The error 
bars represent the mean  SEM of triplicates from one experiment. 
  
4.11. -lactamase-Vpr fusion assay in the context of HIV-1NL4.3: 
Crude cervical mucus plugs 
 
To investigate whether these data (Fig. 9) were influenced by tropism of the infecting 
strains, the fusion assays were repeated using a CXCR4 strain (HIV-1NL4.3 BlaM-Vpr) 
of HIV-1, including T20 treatment as a positive control. The fusion assays showed 
that most cervical mucus plugs potently inhibited HIV-1NL4.3 fusion with the target 
cells despite the donor’s HIV status (Fig. 10A). It should be noted that it was 
impossible to use the same set of samples for all experiments due to limited amount 
of the study samples, some of which got finished before the completion of this study. 
Generally, the percentage fusion was low for HIV-1NL4.3 compared to HIV-1YU-2 (Fig. 
9), thereby recapitulating evidence of selective transmission of R5 viruses over X4 
viruses as reflected by the data from the luciferase assays (Fig. 5). Again, sample 22 
and now with sample 32 but not sample 4, did not block HIV-1NL4.3 fusion with TZMbl 
cells, despite the inhibitory activity they showed in the luciferase assays (Fig. 5). 
Collectively, these data suggest that viral tropism does not influence the inhibition of 
HIV fusion by the cervical mucus, and this rather reflects the variations between and 
within samples.    
 
                                                                                                                
 




Figure 10: Mechanism behind the anti-HIV-1 (HIV-1NL4.3) activity of the crude 
cervical mucus plugs. Crude cervical mucus plugs from the study cohorts were 
probed in triplicates against HIV-1NL4.3 BlaM-Vpr for 1 hour before infecting TZMbl 
cells for 4 hours. After infection, the cells were washed with 10% CO2 independent 
medium and PBS, after which they were trypsinized and re-suspended in 10% CO2 
independent medium. Re-suspended cells were pelleted, PBS-washed and stained 
with CCF4 overnight at room temperature. The CCF4 stained cells were PBS-
washed and fixed with 4% PFA prior to analysis of a -lactamase-mediated CCF4 
cleavage using a multi-parameter LSR ll flow cytometry (BD Biosciences). FACS dot 
plots show the extent of CCF4 cleavage in untreated and treated cells as a reflection 
of HIV-1 fusion with the target cells (A). CCF4 cleavage was quantified by GraphPad 
Prism v5 using One-way ANOVA analysis (nonparametric) (B). The error bars 
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4.12. -lactamase-Vpr fusion assay in the contexts of HIV-1YU-2 and 
HIV-1NL4.3: Purified cervical mucins 
 
The purified cervical mucins showed less potency in HIV-1 inhibition compared to the 
crude cervical mucus plugs (Fig. 5 & Fig. 6). For this reason, the purified cervical 
mucins were subjected into BlaM-Vpr fusion assays at a concentration of 1 mg/ml as 
mentioned above to investigate if this reduced potency relates to a massive influx of 
the HIV-1 strains into the target cells due to mild hindrance of virus-cell fusion by the 
purified cervical mucins. The above-mentioned gating strategy (Fig. 10) was used 
during flow cytometry analysis and shown here (Fig. 11) are the representatives of 
the quantified FACS data using GraphPad Prism v5 (La Jolla, CA, USA).  
 
There was little or no evidence of fusion inhibition in the context of purified cervical 
mucins when compared to the crude cervical mucus plugs (Fig. 11A & 11B). Certain 
samples showed less inhibition of fusion, which could not reach statistical 
significance. Even in the cases of statistical significance, it is very low. For the most 
part and not entirely, the data from the fusion assays recapitulate the data from the 
luciferase assays that crude cervical mucus plugs are more potent in HIV inhibition 
compared to the purified cervical mucins. Together, these data show that the purified 
cervical mucins are less potent because they do not efficiently interfere with the 
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Figure 11: Mechanism behind the anti-HIV-1 (HIV-1YU-2 and HIV-1NL4.3) activity of 
the crude cervical mucins. Purified cervical mucins from the study cohorts were 
probed in triplicates against HIV-1YU-2/HIV-1NL4.3 BlaM-Vpr for 1 hour before infecting 
TZMbl cells for 4 hours. After infection, the cells were washed with 10% CO2 
independent medium and PBS, after which they were trypsinized and re-suspended 
in 10% CO2 independent medium. Re-suspended cells were pelleted, PBS-washed 
and stained with CCF4 overnight at room temperature. The CCF4 stained cells were 
PBS-washed and fixed with 4% PFA prior to analysis of a -lactamase-mediated 
CCF4 cleavage using a multi-parameter LSR ll flow cytometry (BD Biosciences). The 
same gating strategy used in Fig. 9 and 10 was used during flow cytometry analysis. 
The column graphs (A-B) show the extent of CCF4 cleavage in untreated and 
treated cells as a reflection of HIV-1 fusion with the target cells. CCF4 cleavage was 
quantified by GraphPad Prism v5 using nonparametric One-way ANOVA analysis. 
The error bars represent the mean  SEM of triplicates from one experiment.   
 
4.13. Anti-HIV-1 activity of the crude cervical mucins in the context 
of cell-associated virus 
 
The anti-HIV-1 activity of the crude cervical mucus plugs was next investigated in the 
context of cell-to-cell transmission, the most efficient mode of transmission through 
which HIV-1 can escape the therapeutic pressure to which the cell-free HIV-1 strains 
are more susceptible [196, 215, 216]. To model cell-to-cell transmission of HIV-1, 
HEK293T cells were transfected with 2 g of pro-viral plasmid DNA encoding full 
length HIV-1NL3.4-GFP for 24 hours at 37C/5% CO2 [196], after which the transfectants 
were co-cultured with the parental Jurkat T-cells (1:2 ratio) in the presence of the 
crude cervical mucus plugs for the next 24 hours under similar conditions. The 
inhibitory effect of the crude cervical mucus plugs was investigated in the presence 
or absence of efavirenz, a non-nucleoside reverse transcriptase inhibitor, to remove 
GFP background. The anti-viral activity of the crude cervical mucus plugs was 
calculated by subtracting the sample + efavirenz readings from the sample – 
efavirenz readings. 
 
Post-infection, the cells were harvested, washed and fixed with 4% PFA, after which 
the GFP signal was quantified by acquiring 50 000 events using FACS-Calibur flow 
cytometry (BD Biosciences). The data were analysed using FlowJo v10 (Tree Star, 
Ashland, USA) and GraphPad Prism v5 (La Jolla, CA, USA). During analysis, the 
mock treated cells were used to generate a scatter plot (SSC-H/FSC-H) from which 
the live parental Jurkat T-cells were gated while excluding HEK293T cells and cell 
debris (Fig. 12A). The mock treated cells were used to set up a gate, which was 
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applied to the treated cells to determine the GFP signal. Interestingly, with respect to 
the positive control (–Efavirenz), the representative FACS data show that the 
cervical mucus plugs can inhibit cell-to-cell transmission of HIV-1 (Fig. 11A).  
  
Quantification of the FACS data show that this inhibition is independent of the 
donor’s HIV status, since samples from the HIV negative and HIV positive cohorts 
significantly inhibited cell-to-cell transmission of HV-1 (Fig. 11B). However, these 
data do not tell the mechanism of inhibition. But it could be that the components of 
the crude cervical mucus plugs interfere with the virus egress from the producer cells 
(HEK293T) or even aggregate/destroy the released virus particles, thereby depleting 




Figure 12: Anti-HIV-1 activity of the crude cervical mucus in the context of cell-
associated virus. HEK293T cells were transfected for 24 hours with pro-viral DNA 
encoding full length HIV-1NL4.3-GFP and co-cultured with parental Jurkat T-cells for 24 
hours in the presence or absence of cervical mucus plugs from the study cohorts. 
Efavirenz, a non-nucleoside reverse transcriptase inhibitor, was used as a positive 
control. After infection, the cells were harvested, PBS-washed, PFA-fixed and 
analysed by flow cytometry for a GFP signal (A). Samples were assayed in the 
presence or absence of efavirenz, the conditions from which true activity of the 
cervical mucus plugs was derived. GFP signal from parental Jurkat T-cells was 
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normalized to 100% and quantified by GraphPad Prism v5 (B-C). One-way ANOVA 
analysis (nonparametric) was used to compare the means, where the error bars 
represent the mean ± SEM from the triplicates of one experiment.   
 
4.14. Anti-HIV-1 activity of the crude cervical mucus plugs in the 
context of cell-free virus: GFP-based reporter assays 
 
The final step aimed to address a well-recognized phenomenon that cell-to-cell 
transmission can overcome the defensive barriers imposed by the crude cervical 
mucus plugs against cell-free HIV-1 strains [196]. Therefore, we used crude cervical 
mucus plugs against cell-free virus using the same readout as in the context of cell-
to-cell transmission reported in Fig. 12, to allow for an unbiased side-by-side 
comparison of the data from the two assays. HEK293T cells were transfected in 6-
well plates with 2 g of pro-viral plasmid DNA encoding full length HIV-1NL4.3-GFP for 
48 hours at 37C/5% CO2, after which the cell-free HIV-1 particles were harvested 
and passed through a 0.45 m filter (Millipore, Germany) to remove cell debris. Next, 
HIV-1NL4.3-GFP was incubated with the cervical mucus plugs (1:2 ratio) for 1 hour at 
37C/5% CO2 before infecting parental Jurkat T-cells (1x106 cells/well) in triplicates 
for 48 hours under similar conditions. 
 
Following infection, the cells were washed with PBS, fixed with 4% PFA, after which 
the GFP signal was measured by acquiring 50 000 events using FACS-Calibur flow 
cytometry (BD Biosciences). The flow cytometry data analysis was conducted as 
mentioned above (Fig. 12). Like in the luciferase assays (Fig. 5), the crude cervical 
mucus plugs potently inhibited HIV-1 infection, now in a different readout using a 
different cell line, thereby highlighting the consistency of their anti-HIV-1 activity (Fig. 
12A). Quantification of the GFP signal shows that HIV-1 inhibition by all the samples 
is statistically significant (Fig. 13B & 13C). The side-by-side analysis between Fig. 12 
and Fig. 13 shows that, like in several cases [196, 197], cell-to-cell transmission of 
HIV-1 is able to partially overcome the barrier functions imposed by the crude 
cervical mucus plugs against the cell-free HIV-1 strains.  
 
                                                                                                                
 




Figure 13: GFP reporter assay-based analysis of the anti-HIV-1 activity of the 
crude cervical mucus plugs in the context of cell-free virus. Cervical mucus 
plugs were probed against HIV-1NL4.3-GFP in the context of cell-free virus and their 
anti-viral activity was analysed in parental Jurkat T-cells using FACS-Calibur flow 
cytometry (BD Bioscience). After 48 hours, parental Jurkat T-cells were washed with 
PBS and fixed with 4% PFA before flow cytometry analysis. Representative FACS 
dot plots show the levels of GFP signal as a reflection of HIV-1 infection (A). Cervical 
mucus plugs were assayed in the presence or absence of efavirenz, the conditions 
from which their true anti-viral activity was derived. GFP signal was normalized to 
100% and quantified by GraphPad Prism v5 (La Jolla, CA, USA) (B). The error bars 
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Chapter – 5: Discussion 
 
Some years ago, our laboratory set out to investigate why HIV-1 was not transmitted 
through the exchange of oral fluids. At that time, evidence in the literature implicated 
macromolecules such as salivary mucins in the prevention of HIV-1 transmission 
through the exchange of oral fluids [26, 27]. Early studies from our laboratory found 
that crude saliva from the HIV negative subjects and its purified mucins inhibited 
HIV-1 in an in vitro assay, while purified salivary mucins from HIV positive subjects 
did not [29, 192, 193]. Further studies showed that crude breast milk and crude 
cervical mucus plugs did not inhibit HIV-1 in an in vitro assay, but the purified mucins 
from these secretions inhibited HIV-1, regardless of the donor’s HIV status [35, 194, 
195]. These early studies from our laboratory were limited by sporadic pooling of 
samples, use of samples from the subjects who self-declared their HIV status, a lack 
of descriptive statistics for data quantification and the absence of diverse HIV strains 
to reveal inter-individual variations amongst the subjects [36, 121].      
 
This study investigated the anti-HIV-1 activities of crude cervical mucus plugs shed 
during labour, before and after isolation and purification of the cervical mucins from 
HIV negative and HIV positive pregnant women. The cervical mucus plug is 
exclusively produced by the cervix during pregnancy to protect the foeto-maternal 
unit against ascending pathogens from the vaginal canal, failure of which can cause 
life-threatening obstetrical problems [156, 217]. HIV must overcome the mucosal 
barriers before establishing clinical infection [31], and lining these barriers is the 
mucus, a gel-like secretion that covers the epithelia of the female reproductive tract 
(FRT).      
 
Habte et al [35] in our laboratory reported that crude cervical mucus plugs collected 
from HIV negative women in labour do not inhibit HIV-1 infection in an in vitro assay. 
In contrast, using a panel of HIV-1 replication-competent strains, we found that crude 
cervical mucus plugs inhibit cell-free HIV-1 infection, irrespective of the donor’s HIV 
status (Fig. 5). However, the anti-HIV-1 activity showed inter-individual variations 
between individual samples, suggesting a heterogeneity between and within the 
cervical secretions [36, 121, 212]. The cervical mucus plugs exerted a selective anti-
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viral activity against HIV-1, depending on the infecting strain, and showed a 
gatekeeping characteristic that selects for transmission of the R5 strains while 
excluding the X4 strains [214]. There was more potent HIV-1 inhibition within the HIV 
positive cohort compared to the HIV negative cohort, presumably due to retention of 
the HAART regimens [211] and HIV-specific antibodies [174] by the cervical mucus 
plugs collected from the HIV positive cohort. This donor’s HIV status-dependent 
potency of the samples was not seen in the context of cervico-vaginal secretions 
[36]. To a certain extent, this could be due to the exclusion of participants who were 
on ARV drugs, which could be retained by the cervico-vaginal secretions from HIV 
positive women and boost their anti-HIV-1 activity.   
 
HIV-1BaL was more resistant to the cervical mucus plugs from the HIV negative 
cohort (Fig. 5). This resistance was also seen in sample 7 (Fig. 5l) from the HIV 
positive cohort, suggesting that this phenotype is not necessarily determined by the 
donor’s HIV status, but most likely by several factors on which the HIV positive 
subjects may differ: CD4 count, viral load, opportunistic infections and duration of 
HAART. The donor from whom sample 7 was collected had been on HAART 
treatment for 3 years, which is the longest period compared to other donors within 
the HIV positive cohort. Therefore, the suppressive effect of HAART treatment could 
have significantly lowered the HIV-specific antibody titers in this donor’s circulatory 
system [218, 219] and reduced shedding into the cervical mucus plug [174]. Sample 
47 (Fig. 5O) from the HIV positive cohort enhanced SIVmac239 infection compared to 
all other samples, while it consistently proved to be the most potent inhibitory sample 
against the resistant HIV-1BaL. This enhancement was lost following heat inactivation 
of the sample, suggesting that these pro-SIVmac239 factors in sample 47 are proteins 
or glycoproteins. These data highlight the high degree of heterogeneity between and 
within the cervical secretions of the study cohorts as previously reported elsewhere 
[36]. 
 
SIVmac239 was included to extend this study to other lentiviruses that also transmit 
through genital mucosa. When compared to HIV-1 and HIV-2, it resembles HIV-2 in 
several aspects: structural components [220], response to therapy [221] and entry 
mechanisms [222]. Except for sample 47, SIVmac239 assumed a unique and rather 
consistent inhibition profile that began with high sensitivity to mucus, but suddenly 
                                                                                                                
 
61 | P a g e  
 
reached a steady state earlier than the HIV-1 strains (roughly at around 0.125 
mg/ml), after which further increase in cervical mucus plug concentration had little or 
no effect on it (Fig. 5). Presumably, this suggests that SIVmac239 exhibits multiple 
entry mechanisms into cells, upon which it capitalizes to maintain the detectable 
infection levels in the face of increasing cervical mucus plug concentrations. Unlike 
several HIV-1 strains, most HIV-2 and SIV strains have been reported to infect the 
target cells independent of the CD4 receptor and utilize several co-receptors that 
most HIV-1 strains do not utilize [222]. These characteristics, to a certain extent, 
allow these slowly mutating viruses to escape the therapeutic pressure to which 
several HIV-1 strains are more susceptible [223, 224]. HIV-2 and SIV were also 
resistant against submandibular salivary samples that effectively inhibited HIV-1, 
thereby further highlighting the high degree of resemblance between them [225].     
  
The genital mucosa in the FRT exhibit a strict HIV-1 sieve mechanism, which selects 
for transmission of specific HIV-1 strains out of other HIV-1 strains present in the 
ejaculate of an infected male partner [226]. This sieve mechanism selects for 
transmission of the R5 strains while predominantly excludes the X4 strains [213, 
214, 227], thereby explaining why the less diverse R5 strains usually dominate 
during the early stages of HIV infection [228, 229]. In addition to the R5 versus X4 
transmission, our data show that this gatekeeping phenomenon also exists within the 
R5 strains, thus highlighting the high degree of the selective stringency at the genital 
mucosa.  
 
Saba et al [214] reported that the differentiation status of the effector memory CD4 
T-cells is one of the restriction factors that select against the X4 HIV-1 strains in the 
FRT. Our in vitro data suggest that the cervical mucus plugs collected from women 
in labour also exhibit this gatekeeping phenomenon that selects against the CXCR4-
using strains of HIV-1. Following HIV infection, this transmission gate becomes more 
stringent, even for the resistant R5 strains, suggesting an enhanced anti-HIV-1 
specific activity in the cervical mucus plugs collected from the HIV positive cohort. 
Whether this gate keeping phenomenon is exclusively exhibited by the cervical 
mucus plug compared to usual cervical mucus remains to be investigated, but it was 
not observed in the context of cervico-vaginal secretions, regardless of the donor’s 
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HIV and pregnancy statuses respectively [36, 37, 230]. Consequently, in vivo studies 
are needed to investigate the relevance of these data at the physiological level. 
 
In agreement with Habte et al [35], the purified cervical mucins inhibited infection by 
the cell-free HIV-1 strains. This study further showed that the purified cervical mucins 
from the HIV positive cohort also inhibited cell-free HIV-1 strains, suggesting that 
inhibition was independent of the donor’s HIV status. Limited amount of purified 
cervical mucin samples restricted their analysis to two strains of HIV-1 (HIV-1BaL and 
HIV-1NL4.3). The purified cervical mucins showed less potency against cell-free HIV-1 
strains compared to the crude cervical mucus plugs (Fig. 5 & 6). In the case of 
purified cervical mucins, there was no evidence of selective inhibition against the 
infecting HIV-1 strains, nor was there any evidence of tropism-based selective 
transmission (Fig. 6). In summary, the findings of this study differ from those of 
Habte et al [35] in that crude cervical mucus plugs from HIV negative and HIV 
positive cohorts inhibit HIV-1 with inter-individual variations between and within 
samples, and more potently than the purified cervical mucins.   
 
Together, these data suggest that the purified cervical mucins exhibit less potent 
anti-HIV-1 activity compared to the crude cervical mucus plugs and do not mediate 
the tropism-based gatekeeping phenomenon as reflected by the crude cervical 
mucus plugs. Furthermore, if they mediate this phenomenon at all, they probably do 
so synergistically with other components of the crude cervical mucus plugs. Also, 
there was a lesser degree of variation between and within the study subjects in 
terms of the anti-HIV-1 activity of the purified cervical mucins and this was 
independent of the donor’s HIV status. Our results show a certain degree of similarity 
in the anti-viral properties of the cervical mucins between and within the study 
cohorts, independent of the donor’s HIV status. 
 
The anti-HIV molecules typically exert their inhibitory activities in different fashions, 
displaying a broad category of virus-directed and cell-directed inhibitors [197]. To 
investigate the category of inhibitors in which the crude cervical mucus plugs belong, 
the samples were probed against HIV-1NL4.3 under three different conditions using 
the time-of-addition assays (Fig. 8). In condition one, incubation of the target cells 
with cervical mucus plugs for one hour, followed by aspiration of the mucus and 
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infection with HIV-1 for 48 hours showed the least inhibition of infection. This 
inhibition could have been mediated by the cervical mucus plug residues, since the 
cells were not washed following sample aspiration. In condition two, infecting the 
target cells with the virus for one hour prior to incubation with the cervical mucus 
plugs for 48 hours showed the second-best inhibition of infection, most likely due to 
mucus-mediated destabilization of the free-floating and even attached but not yet 
fused HIV-1 particles, thereby depleting the titers available to induce potent infection.  
 
In condition three, the data showed that the crude cervical mucus plugs inhibited 
HIV-1 more potently when the virus was first incubated with the mucus samples for 
one hour prior to infection of the target cells for 48 hours. Together, these data 
suggest that in vivo, in order to effectively protect the foeto-maternal unit, the cervical 
mucus plug must block the pathogens from the vaginal canal before they ascend into 
the cervix and establish the clinical infections. Supporting these observations is the 
orientation assumed by the cervical mucus plug in vivo, whereby the protease, 
immunoglobulin and phagocyte-rich compartment faces towards the pathogen-
infested vaginal canal to clear off the infections while the largely mucoid 
compartment of low cellular content faces towards the supposedly sterile uterus 
[155, 231].         
 
The next step was to address the mechanism through which the crude cervical 
mucus plugs and purified cervical mucins inhibit HIV-1. This step was approached by 
looking at the fusion stage of HIV replication, using the flow cytometry based -
lactamase fusion assay (Fig. 9). Interestingly, most crude cervical mucus plugs 
inhibited the fusion between HIV-1 and the target cells, independent of the donor’s 
HIV status. The crude cervical mucus plugs showed more potent inhibition of fusion 
against HIV-1NL4.3 (Fig. 10) compared to HIV-1YU-2 (Fig. 9), thereby, to a certain 
extent, reflecting similarity to luciferase assays. However, this approach was limited 
by the fact that it was not conducted in parallel with HIV binding assays, thus 
restricting us from distinguishing between the anti-binding and anti-fusion activities of 
the crude cervical mucus plugs. Consequently, it could also be that the HIV-1 strains 
were destabilized or aggregated by the cervical mucus plug components before they 
could even engage the target cells.   
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Some crude cervical mucus plugs showed no evidence of fusion inhibition, despite 
having inhibited the same HIV-1 strains in the luciferase assays. The fact that these 
samples inhibited HIV-1 infection in the luciferase assays but failed to show inhibition 
in the fusion assays suggests a possible action at the post entry stages of HIV-1 
replication, the stages that remain to be investigated. The purified cervical mucins 
showed less to no fusion inhibition of HIV-1 strains, and this activity was comparable 
between the R5 and X4 HIV-1 strains (Fig. 11). Generally, this reflects the less 
potent inhibition of HIV-1 seen in the luciferase assays (Fig. 6). 
 
The discrepancies shown by these specific crude cervical mucus plugs between the 
luciferase and fusion assays highlight another level of heterogeneity between 
samples, which is not only based on the potency of the anti-viral activities but also on 
the mechanisms through which they exert such activities. These discrepancies are 
well-defined between two crude cervical mucus plugs (32 and 22) from the HIV 
negative and HIV positive cohorts respectively (Fig. 9 & 10). The case of sample 22 
can be attributed to the fact that the donor was HIV positive and with three months 
on HAART treatment, which predominantly consists of the regimens that act at the 
post fusion stages of HIV replication [232]. The cervical secretions can retain several 
orally administered HAART regimens [211], antibodies from the maternal blood [174] 
and even foetal cells from the regressing chorionic villi [183].  
 
These data highlight the possible retention of the HAART regimens into sample 22 
[211], which are lacking in fusion inhibitors [232], a circumstance that could explain 
the effect seen in the fusion assays. In the HIV negative cohort, the donor from 
whom sample 32 was collected stood out as the only one who was on antibiotic 
treatment (including co-trimoxazole) due to an E. coli urinary tract infection. The 
direct anti-HIV-1 activity of co-trimoxazole that could also be retained in the cervical 
mucus plugs [233] has not been reported yet, but this antibiotic is used to treat the 
HIV-specific opportunistic infections among the HIV positive individuals [234].  
 
The co-trimoxazole prophylaxis significantly lowered the viral load and improved the 
CD4 counts among the HIV positive Ugandan patients, likely by stabilizing the 
immune system to effectively supress HIV replication [235]. These data highlight the 
anti-HIV role of co-trimoxazole prophylaxis, which could have influenced the anti-
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HIV-1 activity of sample 32. Whether the co-trimoxazole-mediated anti-HIV activity is 
direct or indirect remains to be investigated. The question of why these two samples 
showed differences in anti-HIV-1 activity compared to other samples could be better 
explained by the mass spectrometry analysis, which would presumably reveal 
whether they were deprived of the endogenous or exogenous (in the HIV positive 
cohort) molecules that mediated the anti-fusion activity seen in other samples.    
 
Interestingly, Habte et al [35] in our laboratory did not find the anti-HIV-1 activity in 
the crude cervical mucus plugs, despite them having a repertoire of immunological 
factors [121, 155] and the findings of this study that point to the cervical mucus plug 
as a potent virus-directed inhibitor of HIV-1. Perhaps the difference is that, compared 
to that of Habte et al [35], this study used more sensitive HIV inhibition assays. This 
study was broader, more well-defined in that there were two distinct cohorts, no 
pooling of samples and several independent inhibition assays were conducted. 
Habte et al [35] had fewer samples, which they pooled prior to the inhibition assays. 
The current study shows evidence of a virus-specific pro-viral activity in most 
samples from the HIV negative cohort (Fig. 5), the only cohort that Habte et al [35] 
investigated. The pooling of samples, use of one HIV strain and lack of descriptive 
statistics to effectively judge the differences between the samples and the controls 
limited Habte et al [35] from distinguishing between the pro-viral activity and lack of 
anti-viral activity in their study samples. The use of dosages as the dependent 
variable instead of time would have better illustrated the activities of the study 
samples. So, their data could also be reflecting a pro-viral activity, and not 
necessarily a lack of anti-viral activity by the crude cervical mucus plugs.  
 
The Phase ll report of the International Network for Comparison of the HIV 
Neutralization Assays (NeutNet Report ll) emphasized that there is no single 
neutralization assay that maintains the same sensitivity across a wide spectrum of 
different viruses and neutralizing agents [236]. However, in agreement with Report l 
of NeutNet [237], report ll also showed that the luciferase readout exhibit a broader 
sensitivity across a large spectrum of HIV strains and neutralizing agents compared 
to the p24 readout, which exhibit a narrow sensitivity [236]. Nagashunmugam et al 
[225], whose method was used by Habte et al [35], did not find anti-SIV activity in the 
human submandibular salivary samples, where the highest anti-viral activity of the 
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saliva is found [27]. Using the in vitro luciferase assays, Thomas et al [238] reported 
that the whole human saliva can inhibit SIV in the in vitro assays, thereby 
highlighting the limitations of p24 antigen assay compared to luciferase assay.  
 
The low infection rate of HIV per coital act suggests the active presence of 
endogenous antimicrobials in the crude secretions of the FRT [34]. Proteomic 
studies have identified a spectrum of these antimicrobials in the FRT secretions 
[121, 173, 174], whose ability to supress HIV infection has been reported by several 
independent laboratories [36, 37, 39]. The data presented by Habte et al [35] do not 
support these findings in the context of crude cervical secretions, and their approach 
along with the use of qualitative p24 assays of narrow sensitivity may have limited 
the detection of anti-HIV-1 activity in the crude cervical mucus plugs. The high anti-
HIV-1 potency of the purified cervical mucins reported by Habte et al [35] compared 
to the one reported in this study could be due to the inter-individual variations 
between samples or the differences between the sensitivities of the inhibition assays 
used. 
 
This study went on to characterize the anti-HIV-1 activity of the crude cervical mucus 
plugs in the context of cell-to-cell transmission, the physiological mode of 
transmission through which HIV can escape the therapeutic pressure to which the 
cell-free HIV-1 strains are more susceptible [196, 197]. Due to a limited quantity of 
purified cervical mucin samples, these assays were only carried out using the crude 
cervical mucus plugs. The data showed that the crude cervical mucus plugs can also 
inhibit cell-to-cell transmission of HIV-1NL4.3-GFP irrespective of the donor’s HIV status, 
but with inter-individual variations between samples as seen in the previous assays 
(Fig. 12). For the second time, the crude cervical mucus plugs were probed against 
the cell-free HIV-1NL4.3-GFP, but using a GFP readout as used in the cell-to-cell 
transmission assays to allow an unbiased side-by-side comparison between the data 
from these two modes of HIV transmission. The crude cervical mucus plugs potently 
inhibited HIV-1 infection in the context of cell-free virus (Fig. 13), compared to cell-to-
cell transmission (Fig. 12). 
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The reduction in the anti-HIV-1 activity of the crude cervical mucus plugs in the 
context of cell-to-cell transmission compared to cell-free virus suggest that HIV-1 
overcomes the barrier functions imposed by the cervical mucus plugs against cell-
free strains of HIV-1. This is coherent with several lines of evidence in the context of 
broadly neutralizing antibodies [196, 197, 239]. The mechanism(s) behind the anti-
viral activity of the crude cervical mucus plugs in the case of cell-to-cell transmission 
is not yet known, but it’s more likely that the cervical mucus plug components impair 
the virus egress from the producer cells, destabilize or aggregate the released cell-
free HIV-1 particles and ultimately deplete the viral titers available to engage the 
recipient cells for induction of potent infection. 
 
The fact that the crude cervical mucus plugs consistently maintained a potent 
inhibition against cell-free HIV-1 infection across two independent inhibition assays 
suggests that they are indeed inhibitory against HIV-1 and that their activity is not 
influenced by the use of different inhibition assays. The maintenance of this inhibition 
across these two inhibition assays could be supported by the report that the 
luciferase readout is just as sensitive as the GFP readout, and more standardized 
compared to the error-prone p24 readout [240]. This is one of the strengths of this 
study over that of Habte et al [35], who reported that the crude cervical mucus plugs 
do not inhibit HIV-1 after using a single inhibition assay of narrow sensitivity. 
 
The strength of this study lies in the utilization of more samples, with cohorts of well-
defined HIV status, panel of replication-competent strains of HIV-1 and different 
inhibition assays of high sensitivity. Together, these parameters enabled the 
investigation of the consistency of anti-viral activity among the study samples and 
statistical quantification of the differences between them, thereby uncovering crucial 
information that Habte et al [35] did not find. However, it must be noted that this 
study did not have strict exclusion and inclusion criteria, since collection of samples 
depended on the goodwill of medical staff in busy clinics, thus bringing confounding 
variables into the collected data, which make it difficult to explain the underlying 
inter-individual variations seen between and within the study samples. Further 
limiting this study was a loss of material during purification of the cervical mucins, 
which only enabled probing the purified cervical mucins against two strain of HIV-1. 
This hampered a side-by-side comparison of the anti-viral activities between the 
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crude cervical mucus plugs and purified cervical mucins across the full spectrum of 
the conducted experiments. At a proteomic level, the mass spectrometry analysis of 
the study samples would most likely explain the underlying differences in their anti-
viral activities. Therefore, its use in future studies is highly recommended for rigorous 
investigation of such differences and, in part, identification of the molecules that 
mediate the anti-viral activity in the crude cervical mucus plugs.    
 
The crude cervical mucus plugs were collected in 6 M GuHCl with protease inhibitors 
to inhibit proteolysis of the mucins [198]. The cervical mucins were purified by CsCl 
density gradient ultracentrifugation once, and subjected to Sepharose CL-2B gel-
filtration to enrich the target mucin polymers [201]. The mucin purification profiles for 
both HIV negative and HIV positive cohorts in CsCl were comparable in terms of 
density, glycoprotein and protein contents (Fig. 1A & 1B). This was also the case for 
the Sepharose CL-2B gel-filtration profiles (Fig. 1C & 1D), which were comparable 
for both cohorts, with glycoprotein and protein fractions eluting at approximately the 
same fractions irrespective of the donor’s HIV status. Another comparable activity 
between the purified cervical mucins was seen in the dose-response curves against 
HIV-1 infection (Fig. 5), whereby the purified cervical mucins showed comparable 
inhibition profiles of the two HIV-1 strains, which were independent of the donor’s 
HIV status. Together, these data suggest that the biochemical characteristics of the 
cervical mucins and their anti-HIV-1 activity are comparable between different 
individuals and not necessarily affected by the donor’s HIV status. 
 
The SDS-PAGE was performed to confirm purity of the cervical mucins compared to 
the crude cervical mucus plugs. Following the protein staining, the data showed 
more intense bands for crude cervical mucus plugs, whose intensities increased with 
decreasing molecular weights (Fig. 2A & 2C). However, following the glycoprotein 
staining (Fig. 2B & 2D), the intense bands were seen on top of the gels, after which 
the intensities decreased with decreasing molecular weights, suggesting the 
dominant presence of heavily glycosylated species of higher molecular weight. 
Generally, in terms of protein and glycoprotein intensities, there were no well-defined 
differences between the HIV negative and HIV positive cohorts, other than the inter-
individual variations that could not necessarily be attributed to the donor’s HIV 
status. There was a 130 kDa band common between certain samples irrespective 
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of the donor’s HIV status (Fig. 2A-2D), which could be either IgA or IgG with respect 
to the molecular weight [155, 208].  
 
Another 250 kDa band was exclusively present among certain samples (samples 7, 
12, 14 & 28) from the HIV positive cohort, with varying intensities between them (Fig. 
2C). There was nothing common between these donors in terms of the clinical data 
(see appendix 7.5) and HIV inhibition profiles, and this inconsistent band could be 
better explained by the inter-individual variations on which HIV infection may impact, 
and not exclusively by the HIV infection. Following the mucin purifications (Fig. 2E-
2H), the protein staining confirmed removal of the low molecular species in the V0 
fractions, some of which were retained in the V i fractions (Fig. 2E & 2G). Species of 
higher molecular weight were seen on top of the running gel among the V0 fractions, 
which were confirmed by the PAS staining to be the heavily glycosylated species 
that assumed a typical electrophoretic pattern of the mucins (Fig. 2F & 2H) [201]. 
Several samples showed a 55 kDa band following protein staining regardless of the 
donor’s HIV status, whose intensity decreased following the PAS staining, 
suggesting a lesser degree of glycosylation. This band could be a heavy chain of an 
immunoglobulin [155, 208] or -1 acid glycoprotein [209], at least with respect to the 
molecular weight.  
 
The presence of MUC5AC and MUC5B in the crude cervical mucus plugs and 
purified cervical mucins was confirmed by the Western blots (Fig. 3A-3H). The crude 
cervical mucus plugs from the HIV negative cohort showed the positive bands for 
both MUC5AC and MUC5B, with varying intensities between the individuals (Fig. 3A-
3B). However, sample 1 was negative for MUC5B, even though it was positive for 
MUC5AC, and we cannot rule out from these data whether this was due to the 
absence of MUC5B or its concentration was below the detection level of the 
antibody. Sample 2 showed a more intense band for MUC5B compared to all other 
samples within the HIV negative cohort. Except donor 32, other donors from the HIV 
negative cohort presented with no genitourinary tract infections during 
hospitalization, to which these discrepancies could be attributed. Using 
immunohistochemistry and in situ hybridizations, this inconsistent expression pattern 
of the endo-cervical mucins between individuals was also noted elsewhere [96, 103]. 
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Therefore, it does not necessarily reflect the variations between the detection assays 
but rather the inter-individual variations between the donors from whom the samples 
were collected. More intense bands for MUC5AC and MUC5B were seen in the HIV 
positive cohort (Fig. 3C & 3D), even though some low intense bands were also seen 
among certain samples. 
  
The purified cervical mucins (Fig. 3A-3D) generally showed more intense bands for 
MUC5AC and MUC5B compared to the crude cervical mucus plugs (Fig. 3E-3H). 
This could be due to the mucin enrichment during purification and the removal of 
other molecules found in the crude cervical mucus plugs [121], which could interfere 
with the antibody binding to the mucin antigens. The purified cervical mucins were all 
positive for MUC5AC and MUC5B, irrespective of the donor’s HIV status (Fig. 3E-
3H). There was a well-defined increase in the intensities of MUC5AC from the HIV 
negative to the HIV positive cohort. This observation is in line with the findings of 
Gundavarapu et al [210], who reported an upregulation of MUC5AC expression by 
the HIV’s gp120 in the human bronchial epithelial cells. Such a well-defined shift was 
not seen for MUC5B, other than an inter-individual variation between samples.  
 
These data highlight the selective regulation of MUC5AC and MUC5B genes and 
suggest that their expressions are driven by the different promoters [241]. It is 
recognized that these Western blots were conducted following protein resolution in 
SDS-PAGE gels, as opposed to the typical agarose gels that give better mucin 
resolution [35, 242], and therefore our data do not reflect the best mucin resolution. 
However, our aim was to confirm the presence of the major gel-forming cervical 
mucins in our samples and not necessarily the changes in their electrophoretic 
patterns, an objective that would necessitate the use of agarose gels. It is further 
noted that these data are interpreted in the absence of a loading control due to 
absence of the endogenous controls in the cervical secretions [121]. However, the 
sample loading was controlled by standardizing the sample volume and 
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Chapter – 6: Conclusion 
  
The crude cervical mucus plugs can potently inhibit HIV-1 compared to the purified 
cervical mucins. In the context of crude cervical mucus plugs, depending on the 
infecting HIV-1 strain, this anti-HIV-1 activity varies between and within the individual 
samples, and is more pronounced in the HIV positive cohort. However, such 
variations are absent in the context of the purified cervical mucins. Despite the 
donor’s HIV status, the crude cervical mucus plugs act at different stages of HIV-1 
replication. In the context of cell-to-cell transmission, HIV-1 partially overcomes the 
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Chapter – 7: Appendices  
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7.5. Clinical profiles of the study cohorts: Crude cervical mucus 
plugs 
 















CM1 18.12.1990 Black Negative N/A N/A N/A None 
CM2 29.11.1993 Black Negative N/A N/A N/A None 
CM4 23.03.1995 Black Negative N/A N/A N/A None 
CM5 15.09.1992 Black Negative N/A N/A N/A None 
CM18 15.12.1995 Black Negative N/A N/A N/A None 
CM25 16.12.1995 Black Negative N/A N/A N/A None 
CM32 06.06.1991 Black Negative N/A N/A N/A E. coli UTI 
CM39 10.06.1994 Black Negative N/A N/A N/A None 
 











Viral Load (RNA 
copies/ml) 
Vaginal Infection 
CM7 29.01.1984 Black Positive 36 months 347 Undetectable Genital warts 
CM12 21.03.1996 Black Positive 5 weeks Missing  Missing None 
CM14 15.12.1991 Black Positive 6 months 388 Undetectable None 
CM22 25.06.1989 Black Positive 3 months 270 Undetectable None 
CM28 05.10.1988 Black Positive 1 month 367 36 None 
CM42 23.06.1993 Black Positive 18 months 406 4980 Vaginal discharge 
CM47 27.05.1985 Black Positive 6 months 727 55 None 
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